```
=> b reg
FILE 'REGISTRY' ENTERED AT 17:47:48 ON 21 OCT 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   20 OCT 2009  HIGHEST RN 1189242-76-9
DICTIONARY FILE UPDATES:  20 OCT 2009  HIGHEST RN 1189242-76-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l6
L1  (    394386)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (NC5-NC5 OR NCNC3-NC5
                 OR NC2NC2-NC5 OR N2CNC2-NC5)/ES
L2  (      8932)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (NC5-NC6 OR NC5-NCNC4
                 OR NC5-NC2NC3 OR NC5-N2CNC3)/ES
L3       403278 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (L1 OR L2)
L4              STR
```


```
REP G1=(1-3) C
VAR G2=O/S
VAR G3=7/8/10
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS M6-X9 C  M2-X4 N  AT   7
ECOUNT  IS M6-X9 C  M2-X4 N  AT   9
ECOUNT  IS M6-X9 C  M2-X4 N  AT  11

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  11

STEREO ATTRIBUTES: NONE
L6        12143 SEA FILE=REGISTRY SUB=L3 SSS FUL L4

100.0% PROCESSED  118234 ITERATIONS                      12143 ANSWERS
SEARCH TIME: 00.00.04



=> d que sta l9
L1  (    394386)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (NC5-NC5 OR NCNC3-NC5
                 OR NC2NC2-NC5 OR N2CNC2-NC5)/ES
L2  (      8932)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (NC5-NC6 OR NC5-NCNC4
                 OR NC5-NC2NC3 OR NC5-N2CNC3)/ES
L3       403278 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (L1 OR L2)
L4              STR
```



REP G1=(1-3) C
VAR G2=O/S
VAR G3=7/8/10
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M6-X9 C M2-X4 N AT 7
ECOUNT IS M6-X9 C M2-X4 N AT 9
ECOUNT IS M6-X9 C M2-X4 N AT 11

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE
L6 12143 SEA FILE=REGISTRY SUB=L3 SSS FUL L4
L7 STR



REP G1=(1-3) C
VAR G2=O/S
VAR G3=13/12/17/8/10
REP G4=(0-1) C
VAR G5=C/N
VAR G6=13/12/17
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE
L9 1594 SEA FILE=REGISTRY SUB=L6 SSS FUL L7

100.0% PROCESSED 12143 ITERATIONS 1594 ANSWERS
SEARCH TIME: 00.00.01

=> d que sta l17
L1 (394386)SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON (NC5-NC5 OR NCNC3-NC5
OR NC2NC2-NC5 OR N2CNC2-NC5)/ES
L2 (8932)SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON (NC5-NC6 OR NC5-NCNC4
OR NC5-NC2NC3 OR NC5-N2CNC3)/ES
L3 403278 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON (L1 OR L2)
L4 STR



REP G1=(1-3) C
VAR G2=O/S
VAR G3=7/8/10

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M6-X9 C M2-X4 N AT   7
ECOUNT IS M6-X9 C M2-X4 N AT   9
ECOUNT IS M6-X9 C M2-X4 N AT 11

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE
L6   12143 SEA FILE=REGISTRY SUB=L3 SSS FUL L4
L7   STR



REP G1=(1-3) C
VAR G2=O/S
VAR G3=13/12/17/8/10
REP G4=(0-1) C
VAR G5=C/N
VAR G6=13/12/17
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE
L9   1594 SEA FILE=REGISTRY SUB=L6 SSS FUL L7
L15   STR



REP G1=(1-3) C
VAR G2=O/S
VAR G3=13/12/17/8/10
REP G4=(0-1) C
VAR G5=C/N
VAR G6=13/12/17
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE
L17   932 SEA FILE=REGISTRY SUB=L9 SSS FUL L15

100.0% PROCESSED   1594 ITERATIONS   932 ANSWERS
SEARCH TIME: 00.00.01

=> b zcap

FILE 'ZCAPLUS' ENTERED AT 17:48:00 ON 21 OCT 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 21 Oct 2009 VOL 151 ISS 17
FILE LAST UPDATED: 20 Oct 2009 (20091020/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

ZCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d bib abs hitrn fhitstr l20 tot

L20 ANSWER 1 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:454282 ZCAPLUS
DN 146:462291
TI Preparation of heterocyclyl acrylamide compounds as FabI inhibitors
IN Manning, David Douglas; Decornez, Helene Yvonne; Surman, Matthew David; Martin, Fernando J. L.; Ramnauth, Jailall; Toro, Andras; Berman, Judd M.; Sampson, Peter; Pauls, Henry; Sargent, Bruce Jeremy
PA Affinium Pharmaceuticals, Inc., Can.
SO Can. Pat. Appl., 232 pp.
CODEN: CPXXEB
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CA-----2568914	A1	20051204	2005CA-002568914	20050606
WO--2007053131	A2	20070510	2005WO-US0019805	20050606
WO--2007053131	A3	20070802		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP-----1828167	A2	20070905	2005EP-000858503	20050606
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP--2008505194	T	20080221	2007JP-000543017	20050606
KR--2008016517	A	20080221	2007KR-000700169	20070103
PRAI 2004US-00576945P	P	20040604		
2005WO-US0019805	W	20050606		

OS MARPAT 146:462291
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = monocyclic ring containing 0-2 heteroatoms, bicyclic ring containing 0-4 heteroatoms, tricyclic ring containing heteroatoms containing 0-6 heteroatoms (wherein the rings are independently aliphatic, aromatic, heteroaryl, etc., the heteroatoms are selected from N, S and O and the rings are optionally substituted with alkyl, CN, OCF3, etc.); R = Q1, etc.; R1 = H, alkyl, aryl; R2 = H, alkyl, aryl; R1 and R2 may combine to form a fused ring.; R3 = H, alkyl, aryl; R2 and R3 combine to form a spirocyclic ring.; R5 = H, alkyl, aryl] or their pharmaceutically acceptable salts were prepared. For example, Pd(OAc)2 catalyzed coupling reaction of N-(2-ethoxy-3-trifluoromethoxybenzyl)-N-methylacrylamide, e.g., prepared from 2-trifluoromethoxyphenol in 4 steps, with 7-bromo-3,3-dimethyl-1,3,4,5-tetrahydropyrido[2,3-e][1,4]diazepin-2-one followed by treatment with HCl afforded compound II hydrochloride. In E. coli FabI enzyme inhibition assays, the invention compds. showed the IC50 values ranging from 0.05 μM to 100 μM.
IT **709652-79-9P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclyl acrylamide compds. as FabI inhibitors)
IT **709652-77-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclyl acrylamide compds. as FabI inhibitors)

L20 ANSWER 1 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
IT **709652-79-9P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclyl acrylamide compds. as FabI inhibitors)
RN 709652-79-9 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methyl-2-benzofuranyl)methyl]-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)-(CA INDEX NAME)

Double bond geometry as shown.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L20 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:636869 ZCAPLUS
DN 145:103734
TI Compositions comprising multiple antibiotic agents including a FabI inhibitor, methods of using the same, and preparation of the heterocycle FabI inhibitors
IN Berman, Judd M.; Schmid, Molly B.; Mendlein, John D.; Kaplan, Nachum
PA Affinium Pharmaceuticals, Inc., Can.
SO U.S. Pat. Appl. Publ., 192 pp., which which
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US-20060142265	A1	20060629	2005US-000231298	20050919
WO--2004082586	A2	20040930	2004WO-IB0001261	20040317
WO--2004082586	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI 2003US-00455189P	P	20030317		
2003US-00476970P	P	20030609		
2003US-00488379P	P	20030718		
2004WO-IB0001261	A2	20040317		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 145:103734
GI



II

AB The invention is directed to antibacterial compns. comprising an NADH (or NADPH)-dependent enoyl-acyl carrier protein (ACP) reductase (FabI, previously designated EnvM) inhibitor of formula (Y1)a-A-CH(R1)-NR1CO-L-R2 (I) and at least one other antibiotic/antibacterial agent [L = alkyl, alkenyl, or cycloalkyl which may be substituted by one or more R1; A = (un)substituted bicyclic heteroaryl of 8-12 atoms or a tricyclic ring of 12-16 atoms, containing 1-4 heteroatoms selected from N, S, and O; R1 = H, cyclo/alkyl, alk/aryl; R2 = heterocyclyl; a = 0-4; Y1 = -(CH2)n-CO-NR4R5; R4 = water solubilizing group; R5 = H, cyclo/alkyl; n = 0-4]. The antibacterial composition exhibits a synergistic antibacterial effect compared to its individual components. Thus, bromination of (S)-2-methyl-1,2,4,5-tetrahydropyrido[2,3-e][1,4]diazepin-3-one (preparation given), coupling of the bromide with N-methyl-N-[(3-methylbenzofuran-2-yl)methyl]acrylamide, and acidulation of the free base (no data) with TFA gave pyridodiazepine II•TFA. Selected I inhibited FabI with a Ki < 1 nM, an MIC (minimal inhibitory concentration) < 0.125 μg/mL, and an IC50 < 10 nM.
IT **709652-36-8P**, (E)-(6-{2-[Methyl[(1-methyl-1H-indol-2-yl)methyl]carbamoyl]vinyl}-2-oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl)ethanoic acid **709652-79-9P**, (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-methyl-N-[(3-methylbenzofuran-2-yl)methyl]-2-propenamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

L20 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(bactericide; compns. comprising multiple antibiotic agents and prepn. of heterocycle FabI inhibitor)
IT **709650-75-9P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[(1-propylnaphthalen-2-yl)methyl]-2-propenamide monohydrochloride **709650-79-3P**, (E)-3-[3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-N-methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-2-propenamide monohydrochloride **709650-84-0P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[(naphthalen-2-yl)methyl]-2-propenamide monohydrochloride **709650-86-2P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[(naphthalen-1-yl)methyl]-2-propenamide monohydrochloride **709650-87-3P**, (E)-N-(4-Acetylaminobenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide **709650-91-9P** **709650-92-0P**, (E)-N-(2-Methoxynaphthalen-1-ylmethyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide **709650-95-3P**, (E)-N-Methyl-N-(4-methylnaphthalen-1-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide **709650-98-6P**, (E)-N-(2,3-Dimethylbenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide **709651-00-3P**, (E)-N-(4-Isopropylbenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide **709651-03-6P**, (E)-N-[(Indan-5-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide **709651-07-0P**, (E)-N-[(Indan-5-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-09-2P**, (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-11-6P**, (E)-N-(3,5-Dimethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-12-7P**, (E)-N-[2-(1H-Indol-3-yl)ethyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-13-8P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-(2,4,5-trimethoxybenzyl)-2-propenamide monohydrochloride **709651-15-0P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[(phenanthren-9-yl)methyl]-2-propenamide monohydrochloride **709651-17-2P**, (E)-N-[(Acenaphthen-5-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-18-3P**, (E)-N-(4-Methoxynaphthalen-1-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-19-4P** **709651-20-7P**, (E)-N-(2,5-Dimethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-22-9P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[(quinolin-4-yl)methyl]-2-propenamide monohydrochloride **709651-25-2P**, (E)-N-(4-Ethoxy-3-methoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-27-4P**, (E)-N-(2-Ethoxy-3-methoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-28-5P**, (E)-N-(3,4-Dimethylbenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-29-6P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-(2,4,6-trimethylbenzyl)-2-propenamide monohydrochloride **709651-30-9P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-(2,4,5-trimethylbenzyl)-2-propenamide monohydrochloride **709651-31-0P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[(quinolin-3-yl)methyl]-2-propenamide monohydrochloride **709651-32-1P**, (E)-N-(3,4-Dimethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-

L20 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride
709651-33-2P, (E)-N-[(Benzofuran-2-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-34-3P**,
(E)-N-Methyl-N-(2-methylnaphthalen-1-ylmethyl)-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-35-4P**,
(E)-N-[(Biphenyl-2-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-36-5P**,
(E)-N-[(Biphenyl-3-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-37-6P**,
(E)-N-(2-Ethoxynaphthalen-1-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-38-7P**,
(E)-N-(2-Ethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-40-1P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-(2,3,4-trimethoxybenzyl)-2-propenamide monohydrochloride **709651-41-2P**,
(E)-N-[(2,3-Dihydrobenzo[1,4]dioxin-6-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-42-3P**,
(E)-N-(2,3-Diethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-43-4P**, (E)-N-(3-Ethoxy-2-methoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-44-5P**,
(E)-N-(2-Ethoxy-3-methylbenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-45-6P**,
(E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-N-[(quinolin-5-yl)methyl]-2-propenamide monohydrochloride **709651-46-7P**,
(E)-N-(3-Methoxy-2-propoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-47-8P**,
(E)-N-(3-Methoxy-2-isopropoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-48-9P**,
(E)-N-Methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-49-0P**,
(E)-N-(3-Chloro-2-methoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-50-3P**,
(E)-N-(3-Chloro-2-methoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-51-4P**,
(E)-N-[(2,3-Dihydrobenzo[1,4]dioxin-5-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-52-5P**,
(E)-N-(4,5-Dimethylnaphthalen-1-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-53-6P**,
(E)-N-Methyl-N-(2-methylbenzofuran-3-ylmethyl)-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-56-9P**,
(E)-N-Benzyl-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide **709651-57-0P**,
(E)-N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-58-1P**,
(E)-[7-[2-[Methyl[(1-methyl-1H-indol-2-yl)methyl]carbamoyl]vinyl]-2-oxo-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-4-yl]ethanoic acid ethyl ester monohydrochloride **709651-59-2P**,
(E)-N-(2,3-Dimethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-60-5P**, (E)-N-Methyl-N-(4-methylnaphthalen-1-ylmethyl)-3-(4-

L20 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-61-6P**,
(E)-N-(2-Methoxynaphthalen-1-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-62-7P**,
(R)-(+)-(E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[1-(naphthalen-1-yl)ethyl]-2-propenamide monohydrochloride **709651-63-8P**,
(S)-(-)-(E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[1-(naphthalen-1-yl)ethyl]-2-propenamide monohydrochloride **709651-64-9P**,
(E)-N-[(Benzo[b]thiophen-2-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-65-0P**,
(E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-N-(3-trifluoromethylbenzyl)-2-propenamide monohydrochloride **709651-66-1P**,
(E)-N-(2-Chlorobenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-67-2P**, (E)-N-Methyl-N-(4-methylbenzyl)-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-70-7P**,
(E)-3-[4-(4-Methoxybenzyl)-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-2-propenamide monohydrochloride **709651-71-8P**,
(E)-N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-74-1P**,
(E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[4-[2-(morpholin-4-yl)ethyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride **709651-75-2P**,
(E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[4-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride **709651-76-3P**, (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[4-[3-(morpholin-4-yl)propyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride **709651-77-4P**, (E)-N-(2-Ethoxy-3-methoxybenzyl)-N-methyl-3-[4-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride **709651-80-9P**, (E)-N-(4-Fluoronaphthalen-1-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-81-0P**,
(E)-N-(4-Chloronaphthalen-1-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-82-1P**,
(E)-N-Methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-[4-[3-(morpholin-4-yl)propyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride **709651-83-2P**,
(E)-N-(2-Isopropoxy-3-methoxybenzyl)-N-methyl-3-[4-[3-(morpholin-4-yl)propyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride **709651-84-3P**,
(E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[4-[3-(4-methylpiperazin-1-yl)propyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride **709651-85-4P**, (E)-N-Methyl-N-(2-methylbenzofuran-3-ylmethyl)-3-[4-[3-(morpholin-4-yl)propyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride **709651-86-5P**, (E)-N-[(3-Chlorobenzo[b]thiophen-2-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-87-6P**,
(E)-N-[(5-Chloro-1-methyl-1H-indol-2-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-88-7P** **709651-89-8P**,
(E)-N-[(5-Fluoro-3-methylbenzo[b]thiophen-2-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-90-1P**,
(E)-N-[(5-Chloro-3-methylbenzo[b]thiophen-2-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-93-4P**,

L20 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(E)-N-Methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide **709651-94-5P**, (E)-7-[2-[Methyl[(1-methyl-1H-indol-3-yl)methyl]carbamoyl]vinyl]-2-oxo-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepine-4-carboxylic acid benzyl ester **709651-95-6P**,
(E)-3-(2,4-Dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl)-N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-2-propenamide **709652-14-2P**
709652-15-3P, (E)-N-(2-Isopropoxy-3-methoxybenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide monohydrochloride **709652-16-4P**,
(E)-N-(2-Ethoxy-3-methoxybenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide monohydrochloride
709652-30-2P, (E)-3-[3-(2-Dimethylaminoethyl)-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-2-propenamide **709652-31-3P**,
(E)-N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-32-4P**,
(E)-N-Methyl-N-(4-methylnaphthalen-1-ylmethyl)-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-34-6P**,
(E)-N-(2-Ethoxy-3-methoxybenzyl)-N-methyl-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-35-7P**,
(E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-38-0P**,
(E)-[6-[2-[Methyl[(1-methyl-1H-indol-2-yl)methyl]carbamoyl]vinyl]-2-oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]ethanoic acid sodium salt **709652-39-1P**, (E)-[6-[2-[Methyl[(3-methylbenzo[b]thiophen-2-yl)methyl]carbamoyl]vinyl]-2-oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]ethanoic acid sodium salt **709652-41-5P**,
(E)-N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-[3-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-42-6P**,
(E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[3-[2-(4-methylpiperazin-1-yl]-2-oxoethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-46-0P**, (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[3-[2-(4-methylpiperazin-1-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-51-7P**
709652-55-1P, (E)-N-(2,3-Diethoxybenzyl)-N-methyl-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-56-2P**,
(E)-N-(2-Isopropoxy-3-methoxybenzyl)-N-methyl-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-57-3P**
709652-58-4P, (E)-N-Methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-59-5P**,
(E)-N-Methyl-N-(3-methylbenzofuran-3-ylmethyl)-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,A-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-60-8P**,
(E)-N-(3-Chloro-2-ethoxybenzyl)-N-methyl-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,4-tetranydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-61-9P**,
(E)-N-(4-Fluoronaphthalen-1-ylmethyl)-N-methyl-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-62-0P**,
(E)-N-(2,3-Dimethoxybenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl]-2-propenamide **709652-65-3P**,
(E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-N-[(thieno[3,2-c]pyridin-2-yl)methyl]-2-propenamide **709652-66-4P**, (E)-N-Methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl]-N-[(thieno[3,2-c]pyridin-2-yl)methyl]-2-propenamide **709652-71-1P**,
(E)-N-(1H-Indol-5-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide **709652-72-2P**
, (E)-N-Methyl-N-(1-methylindol-5-ylmethyl)-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
709652-73-3P, (E)-N-(1H-Indol-7-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
709652-74-4P
, (E)-N-Methyl-N-(1-methylindol-7-ylmethyl)-3-(4-methyl-2-oxo-2,3,4,5-

L20 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
709652-75-5P, (E)-N-(1H-Indol-6-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide **709652-77-7P** **709652-80-2P**,
(E)-N-Methyl-N-[(3-methyl-1H-inden-2-yl)methyl]-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bactericide; compns. comprising multiple antibiotic agents and prepn. of heterocycle FabI inhibitor)
IT **709651-73-0**, (E)-3-[4-(4-Methoxybenzyl)-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-2-propenamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(compns. comprising multiple antibiotic agents and preparation of heterocycle FabI inhibitor)
IT **709652-47-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(compns. comprising multiple antibiotic agents and preparation of heterocycle FabI inhibitor)
IT **709650-77-1P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[(1-propylnaphthalen-2-yl)methyl]-2-propenamide **709650-81-7P**,
(E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-2-propenamide
709651-72-9P, (E)-N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
709652-37-9P, (E)-[6-[2-[Methyl[(1-methyl-1H-indol-2-yl]methyl]carbamoyl]vinyl]-2-oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]ethanoic acid ethyl ester **709652-43-7P**,
(E)-[6-[2-[Methyl[(3-methylbenzo[b]thiophen-2-yl)methyl]carbamoyl]vinyl]-2-oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]ethanoic acid
709652-44-8P, (E)-3-[3-(2,2-Dimethoxyethyl)-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-N-methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-2-propenamide **709652-45-9P**
, (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[2-oxo-3-(2-oxoethyl)-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; compns. comprising multiple antibiotic agents and preparation of heterocycle FabI inhibitor)
IT **709652-36-8P**, (E)-[6-[2-[Methyl[(1-methyl-1H-indol-2-yl]methyl]carbamoyl]vinyl]-2-oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]ethanoic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(bactericide; compns. comprising multiple antibiotic agents and preparation of heterocycle FabI inhibitor)
RN 709652-36-8 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-3(2H)-acetic acid, 1,4-dihydro-6-[(1E)-3-[methyl[(1-methyl-1H-indol-2-yl)methyl]amino]-3-oxo-1-propen-1-yl]-2-oxo- (CA INDEX NAME)

Double bond geometry as shown.



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L20 ANSWER 3 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:799437 ZCAPLUS
DN 141:314353
TI Compositions comprising multiple antibiotic agents including a FabI inhibitor, methods of using the same, and preparation of the heterocycle FabI inhibitors
IN Berman, Judd M.; Schmid, Molly B.; Mendlein, John D.; Kaplan, Nachum
PA Affinium Pharmaceuticals, Inc., Can.
SO PCT Int. Appl., 311 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2004082586	A2	20040930	2004WO-IB0001261	20040317
WO--2004082586	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA-----2519429	A1	20040930	2004CA-002519429	20040317
EP-----1608377	A2	20051228	2004EP-000721257	20040317
EP-----1608377	B1	20081001		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
JP--2006523207	T	20061012	2006JP-000506526	20040317
AT------409485	T	20081015	2004AT-000721257	20040317
US-20060142265	A1	20060629	2005US-000231298	20050919
PRAI 2003US-00455189P	P	20030317		
2003US-00476970P	P	20030609		
2003US-00488379P	P	20030718		
2004WO-IB0001261	W	20040317		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 141:314353
GI



I

AB The invention is directed to antibacterial compns. comprising an NADH (or NADPH)-dependent enoyl-acyl carrier protein (ACP) reductase (FabI, previously designated EnvM) inhibitor of formula (Y1)a-A-CH(R1)-NR1CO-L-R2 (I) and at least one other antibiotic/antibacterial agent (L = alkyl, alkenyl, or cycloalkyl which may be substituted by one or more R1; A = (un)substituted bicyclic heteroaryl of 8-12 atoms or a tricyclic ring of 12-16 atoms, containing 1-4 heteroatoms selected from N, S, and O; R1 = cyclo/alkyl, alk/aryl; R2 = heterocyclyl; a = 0-4; Y1 = -(CH2)n-CO-NR4R5; R4 = water solubilizing group; R5 = H, cyclo/alkyl; n = 0-4). The antibacterial composition exhibits a synergistic antibacterial effect compared to its individual components. Thus, reacting 7-Bromo-3,3-dimethyl-1,3,4,5-tetrahydropyrido[2,3-e][1,4]diazepin-2-one (preparation given) with N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]acrylamide (preparation given), followed by acidulation gave diazepinone salt I·HCl. Selected I inhibited FabI with a Ki < 1 nM, an MIC (minimal inhibitory concentration) < 0.125 μg/mL, and an IC50 < 10 nM.

L20 ANSWER 3 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
IT **709652-36-8P**, (E)-6-[2-[Methyl[(1-methyl-1H-indol-2-yl)methyl]carbamoyl]vinyl]-2-oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]ethanoic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(bactericide; compns. comprising multiple antibiotic agents and preparation of heterocycle FabI inhibitor)
IT **709650-75-9P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[(1-propylnaphthalen-2-yl)methyl]-2-propenamide monohydrochloride **709650-79-3P**, (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-2-propenamide monohydrochloride **709650-84-0P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[(naphthalen-2-yl)methyl]-2-propenamide monohydrochloride **709650-86-2P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[(naphthalen-1-yl)methyl]-2-propenamide monohydrochloride **709650-87-3P**, (E)-N-(4-Acetylaminobenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide **709650-91-9P**, (E)-N-(4-Methylsulfonylbenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide **709650-92-0P**, (E)-N-(2-Methoxynaphthalen-1-ylmethyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide **709650-95-3P**, (E)-N-Methyl-N-(4-methylnaphthalen-1-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide **709650-98-6P**, (E)-N-(2,3-Dimethylbenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide **709651-00-3P**, (E)-N-(4-Isopropylbenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide **709651-03-6P**, (E)-N-[(Indan-5-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide **709651-07-0P**, (E)-N-[(Indan-5-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-09-2P**, (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-11-6P**, (E)-N-(3,5-Dimethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-12-7P**, (E)-N-[2-(1H-Indol-3-yl)ethyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-13-8P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-(2,4,5-trimethoxybenzyl)-2-propenamide monohydrochloride **709651-15-0P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[(phenanthren-9-yl)methyl]-2-propenamide monohydrochloride **709651-17-2P**, (E)-N-[(Acenaphthen-5-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-18-3P**, (E)-N-(4-Methoxynaphthalen-1-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-19-4P**, (E)-N-[(Benzodioxol-5-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-20-7P**, (E)-N-(2,5-Dimethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-22-9P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[(quinolin-4-yl)methyl]-2-propenamide monohydrochloride **709651-25-2P**, (E)-N-(4-Ethoxy-3-methoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-27-4P**, (E)-N-(2-Ethoxy-3-methoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-28-5P**, (E)-N-(3,4-Dimethylbenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-29-6P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-(2,4,6-trimethylbenzyl)-2-propenamide monohydrochloride **709651-30-9P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-(2,4,5-trimethylbenzyl)-2-propenamide monohydrochloride **709651-31-0P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-N-[(quinolin-3-yl)methyl]-2-propenamide monohydrochloride **709651-32-1P**, (E)-N-(3,4-Dimethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-33-2P**, (E)-N-[(Benzofuran-2-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-34-3P**, (E)-N-Methyl-N-(2-methylnaphthalen-1-ylmethyl)-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-35-4P**, (E)-N-[(Biphenyl-2-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-36-5P**, (E)-N-[(Biphenyl-3-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-37-6P**, (E)-N-(2-Ethoxynaphthalen-1-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-38-7P**, (E)-N-(2-Ethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-40-1P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-(2,3,4-trimethoxybenzyl)-2-propenamide monohydrochloride **709651-41-2P**, (E)-N-[(2,3-Dihydrobenzo[1,4]dioxin-6-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-42-3P**, (E)-N-(2,3-Diethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-43-4P**, (E)-N-(3-Ethoxy-2-methoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-44-5P**, (E)-N-(2-Ethoxy-3-methylbenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-45-6P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-N-[(quinolin-5-yl)methyl]-2-propenamide monohydrochloride **709651-46-7P**, (E)-N-(3-Methoxy-2-propoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-47-8P**, (E)-N-(3-Methoxy-2-isopropoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-48-9P**, (E)-N-Methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-49-0P**, (E)-N-(3-Chloro-2-methoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-50-3P**, (E)-N-(3-Chloro-2-ethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-51-4P**, (E)-N-[(2,3-Dihydrobenzo[1,4]dioxin-5-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-52-5P**, (E)-N-(4,5-Dimethylnaphthalen-1-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-53-6P**, (E)-N-Methyl-N-(2-methylbenzofuran-3-ylmethyl)-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-56-9P**, (E)-N-Benzyl-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide **709651-57-0P**,

L20 ANSWER 3 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(E)-N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-58-1P**, (E)-[7-[2-[Methyl[(1-methyl-1H-indol-2-yl)methyl]carbamoyl]vinyl]-2-oxo-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-4-yl]ethanoic acid ethyl ester monohydrochloride **709651-59-2P**, (E)-N-(2,3-Dimethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-60-5P**, (E)-N-Methyl-N-(4-methylnaphthalen-1-ylmethyl)-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-61-6P**, (E)-N-(2-Methoxynaphthalen-1-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-62-7P**, (R)-(+)-(E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[1-(naphthalen-1-yl)ethyl]-2-propenamide monohydrochloride **709651-63-8P**, (S)-(-)-(E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[1-(naphthalen-1-yl)ethyl]-2-propenamide monohydrochloride **709651-64-9P**, (E)-N-[(Benzo[b]thiophen-2-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-65-0P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-(3-trifluoromethylbenzyl)-2-propenamide monohydrochloride **709651-66-1P**, (E)-N-(2-Chlorobenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-67-2P**, (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-70-7P**, (E)-3-[4-(4-Methoxybenzyl)-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-2-propenamide monohydrochloride **709651-71-8P**, (E)-N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-74-1P**, (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[4-[2-(morpholin-4-yl)ethyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride **709651-75-2P**, (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[4-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride **709651-76-3P**, (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[4-[3-(morpholin-4-yl)propyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride **709651-77-4P**, (E)-N-(2-Ethoxy-3-methoxybenzyl)-N-methyl-3-[4-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride **709651-80-9P**, (E)-N-(4-Fluoronaphthalen-1-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-81-0P**, (E)-N-(4-Chloronaphthalen-1-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-82-1P**, (E)-N-Methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-[4-[3-(morpholin-4-yl)propyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride **709651-83-2P**, (E)-N-(2-Isopropoxy-3-methoxybenzyl)-N-methyl-3-[4-[3-(morpholin-4-yl)propyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride **709651-84-3P**, (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[4-[3-(4-methylpiperazin-1-yl)propyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride **709651-85-4P**, (E)-N-Methyl-N-(2-methylbenzofuran-3-ylmethyl)-3-[4-[3-(morpholin-4-yl)propyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride **709651-86-5P**, (E)-N-[(3-Chlorobenzo[b]thiophen-2-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-87-6P**, (E)-N-[(5-Chloro-1-methyl-1H-indol-2-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-88-7P**, (E)-N-[(1,7-Dimethyl-1H-indol-2-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-

L20 ANSWER 3 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-89-8P**,
(E)-N-[(5-Fluoro-3-methylbenzo[b]thiophen-2-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-90-1P**,
(E)-N-[(5-Chloro-3-methylbenzo[b]thiophen-2-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride **709651-93-4P**,
(E)-N-Methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide **709651-94-5P**, (E)-7-[2-[Methyl[(1-methyl-1H-indol-3-yl)methyl]carbamoyl]vinyl]-2-oxo-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepine-4-carboxylic acid benzyl ester **709651-95-6P**,
(E)-3-(2,4-Dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl)-N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-2-propenamide **709652-14-2P**,
(E)-N-(3-Methoxy-2-propoxybenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide monohydrochloride **709652-15-3P**, (E)-N-(2-Isopropoxy-3-methoxybenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide monohydrochloride **709652-16-4P**,
(E)-N-(2-Ethoxy-3-methoxybenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide monohydrochloride **709652-30-2P**, (E)-3-[3-(2-Dimethylaminoethyl)-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-2-propenamide **709652-31-3P**,
(E)-N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-32-4P**,
(E)-N-Methyl-N-(4-methylnaphthalen-1-ylmethyl)-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-34-6P**,
(E)-N-(2-Ethoxy-3-methoxybenzyl)-N-methyl-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-35-7P**,
(E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-38-0P**,
(E)-[6-[2-[Methyl[(1-methyl-1H-indol-2-yl)methyl]carbamoyl]vinyl]-2-oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]ethanoic acid sodium salt **709652-39-1P**, (E)-[6-[2-[Methyl[(3-methylbenzo[b]thiophen-2-yl)methyl]carbamoyl]vinyl]-2-oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]ethanoic acid sodium salt **709652-41-5P**,
(E)-N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-[3-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-42-6P**,
(E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[3-[2-(4-methylpiperazin-1-yl]-2-oxoethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-46-0P**,
(E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[3-[2-(4-methylpiperazin-1-yl]ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-51-7P**,
(E)-N-(2-Ethoxy-3-methoxybenzyl)-N-methyl-3-[3-[3-(morpholin-4-yl]propyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-55-1P**,
(E)-N-(2,3-Diethoxybenzyl)-N-methyl-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-56-2P**,
(E)-N-(2-Isopropoxy-3-methoxybenzyl)-N-methyl-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-57-3P**,
(E)-N-(3-Methoxy-2-propoxybenzyl)-N-methyl-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-58-4P**,
(E)-N-Methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-59-5P**,
(E)-N-Methyl-N-(2-methylbenzofuran-3-ylmethyl)-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,A-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-60-8P**,
(E)-N-(3-Chloro-2-ethoxybenzyl)-N-methyl-3-[3-[2-(morpholin-4-yl)ethyl]-2-

L20 ANSWER 3 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-61-9P**,
(E)-N-(4-Fluoronaphthalen-1-ylmethyl)-N-methyl-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-62-0P**
, (E)-N-(2,3-Dimethoxybenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide **709652-65-3P**,
(E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[(thieno[3,2-c]pyridin-2-yl)methyl]-2-propenamide **709652-66-4P**, (E)-N-Methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-N-[(thieno[3,2-c]pyridin-2-yl)methyl]-2-propenamide **709652-71-1P**,
(E)-N-(1H-Indol-5-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide **709652-72-2P**
, (E)-N-Methyl-N-(1-methylindol-5-ylmethyl)-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-2-propenamide **709652-73-3P**, (E)-N-(1H-Indol-7-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide **709652-74-4P**, (E)-N-Methyl-N-(1-methylindol-7-ylmethyl)-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide **709652-75-5P**,
(E)-N-(1H-Endol-6-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide **709652-79-9P**
, (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-methyl-N-[(3-methylbenzofuran-2-yl)methyl]-2-propenamide **709652-80-2P**,
(E)-N-Methyl-N-[(3-methyl-1H-inden-2-yl)methyl]-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bactericide; compns. comprising multiple antibiotic agents and prepn. of heterocycle FabI inhibitor)
IT **709651-73-0**, (E)-3-[4-(4-Methoxybenzyl)-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-2-propenamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(compns. comprising multiple antibiotic agents and preparation of heterocycle FabI inhibitor)
IT **709650-77-1P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[(1-propylnaphthalen-2-yl)methyl]-2-propenamide **709650-81-7P**,
(E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-2-propenamide **709651-72-9P**, (E)-N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide **709652-37-9P**, (E)-[6-[2-[Methyl[(1-methyl-1H-indol-2-yl)methyl]carbamoyl]vinyl]-2-oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]ethanoic acid ethyl ester **709652-43-7P**,
(E)-[6-[2-[Methyl[(3-methylbenzo[b]thiophen-2-yl)methyl]carbamoyl]vinyl]-2-oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]ethanoic acid **709652-44-8P**, (E)-3-[3-[3-(2,2-Dimethoxyethyl)-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-N-methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-2-propenamide **709652-45-9P**
, (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[2-oxo-3-(2-oxoethyl)-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; compns. comprising multiple antibiotic agents and preparation of heterocycle FabI inhibitor)
IT **709652-36-8P**, (E)-[6-[2-[Methyl[(1-methyl-1H-indol-2-yl)methyl]carbamoyl]vinyl]-2-oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]ethanoic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(bactericide; compns. comprising multiple antibiotic agents and preparation of heterocycle FabI inhibitor)
RN 709652-36-8 ZCAPLUS

L20 ANSWER 3 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Pyrido[2,3-d]pyrimidine-3(2H)-acetic acid, 1,4-dinydro-6-[(1E)-3-[methyl[(1-methyl-1H-indol-2-yl)methyl]amino]-3-oxo-1-propen-1-yl]-2-oxo- (CA INDEX NAME)

Double bond geometry as shown.



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 4 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:515512 ZCAPLUS
DN 141:71572
TI Preparation of heterocyclic compounds as antibacterial agents
IN Berman, Judd; Sampson, Peter; Pauls, Heinz W.; Ramnauth, Jailall; Manning, David Douglas; Surman, Matthew David; Xie, Dejian; Decornez, Helene Yvonne
PA Affinium Pharmaceuticals, Inc., Can.
SO PCT Int. Appl., 223 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2004052890	A1	20040624	2003WO-US0038706	20031205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA-----2508792	A1	20040624	2003CA-002508792	20031205
AU--2003298937	A1	20040630	2003AU-000298937	20031205
EP-----1575951	A1	20050921	2003EP-000796699	20031205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LI, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP--2006513262	T	20060420	2005JP-000508475	20031205
US-20060183908	A1	20060817	2003US-000537747	20031205
PRAI 2002US-004314O6P	P	20021206		
2003US-00465583P	P	20030425		
2003WO-US0038706	W	20031205		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 141:71572
AB Compds. of formula (Yl)a-A-CH(R1)-NR1CO-L-R2 [I; L = a bond, is alkyl, alkenyl, or cycloalkyl which may be substituted with one or more R1; A = a bicyclic heteroaryl ring of 8-12 atoms or a tricyclic ring oft 12-16 atoms, wherein the heteroaryl rings contain 1-4 heteroatoms selected from N, S, and O, and wherein the heteroaryl rings are optionally substituted with one or more groups selected from C1-4 alkyl, CH2OH, OR, SR, CN, N(R)2, CH2N(R)2, NO2, CF3, CO2R, CON(R)2, COR, NRC(O)R, F, Cl, Br, iodo, and S(O)rCF3 (R = H, alkyl, alkaryl; r = 0-2); R1 = H, alkyl, cycloalkyl, aryl, or alkaryl; R2 = heterocyclyl] or pharmaceutically acceptable salts thereof are prepared. These compds. inhibit an NADH (or NADPH)-dependent enoyl-acyl carrier protein (ACP) reductase (FabI, previously designated EnvM) which is believed to be a major biosynthetic enzyme and is a key regulatory point in the overall synthetic pathway of bacterial fatty acid biosynthesis and catalyzes the final step of fatty acid biosynthesis in some bacteria. The present invention also relates to inhibitors and compns. comprising inhibitors of enzymes similar to FabI either structurally or functionally, such as, for example, FabK which is also believed to play a role in bacterial fatty acid synthesis. In another aspect of the present invention, the antibacterial compds. of the present invention may be used to disinfect an inanimate surface by administering the antibacterial compound to the inanimate surface. Thus, (E)-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)acrylic acid hydrochloride was condensed with N-methyl-N-(1-propylnaphthalen-2-ylmethyl)amine in DMF using diisopropylethylamine, 1-hydroxybenzotriazole hydrate, and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride at room temperature for 18 h to give, after silica gel chromatog., 41% (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[(1-propylnaphthalen-2-yl)methyl]acrylamide as a glassy orange solid and as a mixture of amide rotamers. The compds. I inhibit FabI with a Ki of about 5 pM or less.
IT **709652-36-8P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of heterocyclic compds. as enoyl-acyl carrier protein reductase FabI inhibitors and antibacterial agents)
IT **709652-37-9P** **709652-40-4P** **709652-43-7P**

L20 ANSWER 4 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

709652-44-8P **709652-45-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of heterocyclic compds. as enoyl-acyl carrier protein reductase FabI inhibitors and antibacterial agents)

IT **709650-75-9P** **709650-77-1P** **709650-79-3P**
709650-81-7P **709650-84-0P** **709650-86-2P**
709650-87-3P **709650-91-9P** **709650-92-0P**
709650-95-3P **709650-98-6P** **709651-00-3P**
709651-03-6P **709651-07-0P** **709651-09-2P**
709651-11-6P **709651-12-7P** **709651-13-8P**
709651-15-0P **709651-17-2P** **709651-18-3P**
709651-19-4P **709651-20-7P** **709651-22-9P**
709651-25-2P **709651-27-4P** **709651-28-5P**
709651-29-6P **709651-30-9P** **709651-31-0P**
709651-32-1P **709651-33-2P** **709651-34-3P**
709651-35-4P **709651-36-5P** **709651-37-6P**
709651-38-7P **709651-40-1P** **709651-41-2P**
709651-42-3P **709651-43-4P** **709651-44-5P**
709651-45-6P **709651-46-7P** **709651-47-8P**
709651-48-9P **709651-49-0P** **709651-50-3P**
709651-51-4P **709651-52-5P** **709651-53-6P**
709651-55-8P **709651-56-9P** **709651-57-0P**
709651-58-1P **709651-59-2P** **709651-60-5P**
709651-61-6P **709651-62-7P** **709651-63-8P**
709651-64-9P **709651-65-0P** **709651-66-1P**
709651-67-2P **709651-70-7P** **709651-71-8P**
709651-72-9P **709651-74-1P** **709651-75-2P**
709651-76-3P **709651-77-4P** **709651-80-9P**
709651-81-0P **709651-82-1P** **709651-83-2P**
709651-84-3P **709651-85-4P** **709651-86-5P**
709651-87-6P **709651-88-7P** **709651-89-8P**
709651-90-1P **709651-93-4P** **709651-94-5P**
709651-95-6P **709652-14-2P** **709652-15-3P**
709652-16-4P **709652-30-2P** **709652-31-3P**
709652-32-4P **709652-33-5P** **709652-34-6P**
709652-35-7P **709652-38-0P** **709652-39-1P**
709652-41-5P **709652-42-6P** **709652-46-0P**
709652-47-1P **709652-50-6P** **709652-51-7P**
709652-55-1P **709652-56-2P** **709652-57-3P**
709652-58-4P **709652-59-5P** **709652-60-8P**
709652-61-9P **709652-62-0P** **709652-65-3P**
709652-66-4P **709652-71-1P** **709652-72-2P**
709652-73-3P **709652-74-4P** **709652-75-5P**
709652-77-7P **709652-79-9P** **709652-80-2P**
709652-87-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as enoyl-acyl carrier protein reductase FabI inhibitors and antibacterial agents)

IT **709651-73-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of heterocyclic compds. as enoyl-acyl carrier protein reductase FabI inhibitors and antibacterial agents)

IT **709652-36-8P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of heterocyclic compds. as enoyl-acyl carrier protein reductase FabI inhibitors and antibacterial agents)

RN 709652-36-8 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-3(2H)-acetic acid, 1,4-dihydro-6-[(1E)-3-[methyl[(1-methyl-1H-indol-2-yl)methyl]amino]-3-oxo-1-propen-1-yl]-2-oxo- (CA INDEX NAME)

Double bond geometry as shown.

L20 ANSWER 4 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr l31 tot

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:636869 ZCAPLUS
DN 145:103734
TI Compositions comprising multiple antibiotic agents including a FabI inhibitor, methods of using the same, and preparation of the heterocycle FabI inhibitors
IN Berman, Judd M.; Schmid, Molly B.; Mendlein, John D.; Kaplan, Nachum
PA Affinium Pharmaceuticals, Inc., Can.
SO U.S. Pat. Appl. Publ., 192 pp., which which
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US-20060142265	A1	20060629	2005US-000231298	20050919 <--
WO--2004082586	A2	20040930	2004WO-IB0001261	20040317 <--
WO--2004082586	A3	20041223		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI 2003US-00455189P P 20030317 <--
2003US-00476970P P 20030609 <--
2003US-00488379P P 20030718 <--
2004WO-IB0001261 A2 20040317
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 145:103734
GI



II

AB The invention is directed to antibacterial comprns. comprising an NADH (or NADPH)-dependent enoyl-acyl carrier protein (ACP) reductase (FabI, previously designated EnvM) inhibitor of formula (Y1)a-A-CH(R1)-NR1CO-L-R2 (I) and at least one other antibiotic/antibacterial agent [L = alkyl, alkenyl, or cycloalkyl which may be substituted by one or more R1; A = (un)substituted bicyclic heteroaryl of 8-12 atoms or a tricyclic ring of 12-16 atoms, containing 1-4 heteroatoms selected from N, S, and O; R1 = H, cyclo/alkyl, alk/aryl; R2 = heterocyclyl; a = 0-4; Y1 = -(CH2)n-CO-NR4R5; R4 = water solubilizing group; R5 = H, cyclo/alkyl; n = 0-4]. The antibacterial composition exhibits a synergistic antibacterial effect compared to its individual components. Thus, bromination of (S)-2-methyl-1,2,4,5-tetrahydropyrido[2,3-e][1,4]diazepin-3-one (preparation given), coupling of the bromide with N-methyl-N-[(3-methylbenzofuran-2-yl)methyl]acrylamide, and acidulation of the free base (no data) with TFA gave pyridodiazepine II•TFA. Selected I inhibited FabI with a Ki < 1 nM, an MIC (minimal inhibitory concentration) < 0.125 μg/mL, and an IC50 < 10 nM.

IT **620175-32-8** **620175-33-9** **620175-34-0**
620175-38-4 **620175-40-8** **620175-43-1**

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-40-8 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-3-benzofuranyl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-43-1 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[1-(1-methyl-1H-indol-2-yl)ethyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-44-2 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[1-(1-methyl-1H-indol-3-yl)ethyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 1056188-56-7 ZCAPLUS
CN 2-Propenamide, N-[(2,3-dihydro-1,3-dimethyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
620175-44-2 **1056188-56-7**
RL: PRPH (Prophetic)
(Compns. comprising multiple antibiotic agents including a FabI inhibitor, methods of using the same, and prepn. of the heterocycle FabI inhibitors)
RN 620175-32-8 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-33-9 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-34-0 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-38-4 ZCAPLUS
CN 2-Propenamide, N-(3-benzofuranylmethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT **894851-52-6P**, (E)-N-(3-Isopropyl-2-propoxybenzyl)-N-methyl-3-(2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(bactericide; compns. comprising multiple antibiotic agents and preparation of heterocycle FabI inhibitor)
RN 894851-52-6 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[[3-(1-methylethyl)-2-propoxyphenyl]methyl]-3-(2,3,4,5-tetrahydro-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



IT **486397-21-1P**, (E)-N-Methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-N-[(1,2,7-trimethyl-1H-indol-3-yl)methyl]-2-propenamide
620174-10-9P, (E)-N-Methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(3-methyl-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl)-2-propenamide
620174-11-0P, (E)-N-Methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(3-methyl-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl)-2-propenamide
620174-23-4P, (E)-N-(1H-Indol-3-ylmethyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-26-7P, (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-29-0P, (E)-N-[[1-(2-Dimethylaminoethyl)-1H-indol-3-yl]methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide **620174-33-6P** **620174-40-5P**, (E)-N-Methyl-N-[(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-42-7P, (E)-N-[(1-Ethyl-5-fluoro-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-43-8P, (E)-N-[(5-Fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-44-9P, (E)-N-[(6-Fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-45-0P, (E)-N-[(7-Fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-63-2P, (E)-N-[(7-Chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-65-4P, (E)-N-[(7-Chloro-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-67-6P, (E)-2-Methyl-N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide **620174-69-8P**, (E)-3-Methyl-N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide **620174-73-4P**, (E)-N-Methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-2-propenamide
620174-75-6P, (E)-N-[(1-(2-Hydroxyethyl)-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-77-8P, (E)-N-Methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(8-

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-2-propenamide
620174-79-0P, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-89-2P, (E)-N-[(2-Chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-91-6P, (E)-N-(Naphthalen-2-ylmethyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-94-9P, (E)-N-(Benzofuran-2-ylmethyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-98-3P, (E)-N-[(5-Chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-99-4P, (E)-N-[(6-Chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-00-0P, (E)-N-[(1,7-Dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-01-1P, (E)-N-[(1,6-Dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-02-2P, (E)-N-[(1,4-Dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-03-3P, (E)-N-[(1,5-Dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-04-4P, (E)-N-[(7-Methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-05-5P, (E)-N-[(7-Hydroxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-06-6P, (E)-N-[(4-Chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-07-7P, (E)-N-[(4-Methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-08-8P, (E)-N-[(5-Methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-10-2P, (E)-N-[(6-Methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-12-4P, (E)-N-[(3,3-Dimethyl-3H-inden-1-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-20-4P, (E)-N-[(4-Fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-22-6P, (E)-N-(Quinolin-3-ylmethyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-24-8P, (E)-N-(Naphthalen-1-ylmethyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-26-0P, (E)-N-Methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-[3-(2-methoxyethyl)-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide **620175-28-2P**,
(E)-N-[(1-Methyl-1H-indol-3-yl)methyl]-N-methyl-3-(6-methoxycarbonyl-7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-39-5P **768378-25-2P** **768378-26-3P**
768378-29-6P **768378-52-5P** **768378-54-7P**
768378-60-5P **768378-61-6P**,
N-Methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)acrylamide **768378-62-7P**,
N-Methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)acrylamide **768378-63-8P**,
N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)acrylamide
768378-64-9P, N-[(Acenaphthen-5-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)acrylamide
768378-65-0P, N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]acrylamide **768378-66-1P**,
N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)acrylamide **894851-14-0P**
894851-19-5P **894851-24-2P** **894851-29-7P**,
(E)-N-(3-Chloro-2-propoxybenzyl)-3-(3,3-dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-methyl-2-propenamide hydrochloride
894851-36-6P **894851-44-6P** **894851-49-1P**
894851-53-7P **894851-56-0P** **894851-70-8P**
894851-80-0P, (E)-N-[(3-Ethylbenzofuran-2-yl)methyl]-N-methyl-3-(2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide hydrochloride **894851-84-4P** **894851-90-2P**

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620174-11-0 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(1,2,3,4-tetrahydro-3-methyl-2-oxopyrido[2,3-d]pyrimidin-6-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-23-4 ZCAPLUS
CN 2-Propenamide, N-(1H-indol-3-ylmethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-26-7 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-(phenylmethyl)-1H-indol-3-yl]methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 620174-10-9 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(1,2,3,4-tetrahydro-3-methyl-2-oxopyrido[2,3-d]pyrimidin-6-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 486397-21-1 ZCAPLUS
CN 2-Propenamide, N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-N-[(1,2,7-trimethyl-1H-indol-3-yl)methyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-29-0 ZCAPLUS
CN 2-Propenamide, N-[[3-[2-(dimethylamino)ethyl]-1H-indol-3-yl]methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-33-6 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methylbenzo[b]thien-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-40-5 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 620174-42-7 ZCAPLUS
CN 2-Propenamide, N-[(1-ethyl-5-fluoro-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620174-43-8 ZCAPLUS
CN 2-Propenamide, N-[(5-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-44-9 ZCAPLUS
CN 2-Propenamide, N-[(6-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-45-0 ZCAPLUS
CN 2-Propenamide, N-[(7-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620174-69-8 ZCAPLUS
CN 2-Butenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-73-4 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(6,7,8,9-tetrahydro-8-oxo-5H-pyrido[2,3-b]azepin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-75-6 ZCAPLUS
CN 2-Propenamide, N-[(1-(2-hydroxyethyl)-1H-indol-3-yl]methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-77-8 ZCAPLUS

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620174-63-2 ZCAPLUS
CN 2-Propenamide, N-[(7-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-65-4 ZCAPLUS
CN 2-Propenamide, N-[(7-chloro-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-67-6 ZCAPLUS
CN 2-Propenamide, N,2-dimethyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(6,7,8,9-tetrahydro-8-oxo-5H-pyrido[2,3-b]azepin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-79-0 ZCAPLUS
CN 2-Propenamide, N-[(1-ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-89-2 ZCAPLUS
CN 2-Propenamide, N-[(2-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-91-6 ZCAPLUS
CN 2-Propenamide, N-methyl-N-(2-naphthalenylmethyl)-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620174-94-9 ZCAPLUS
CN 2-Propenamide, N-(2-benzofuranylmethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-98-3 ZCAPLUS
CN 2-Propenamide, N-[(5-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-99-4 ZCAPLUS
CN 2-Propenamide, N-[(6-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620175-04-4 ZCAPLUS
CN 2-Propenamide, N-[(7-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-05-5 ZCAPLUS
CN 2-Propenamide, N-[(7-hydroxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-06-6 ZCAPLUS
CN 2-Propenamide, N-[(4-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 620175-00-0 ZCAPLUS
CN 2-Propenamide, N-[(1,7-dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-01-1 ZCAPLUS
CN 2-Propenamide, N-[(1,6-dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-02-2 ZCAPLUS
CN 2-Propenamide, N-[(3,4-dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-03-3 ZCAPLUS
CN 2-Propenamide, N-[(1,5-dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 620175-07-7 ZCAPLUS
CN 2-Propenamide, N-[(4-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-08-8 ZCAPLUS
CN 2-Propenamide, N-[(5-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-10-2 ZCAPLUS
CN 2-Propenamide, N-[(6-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-12-4 ZCAPLUS
CN 2-Propenamide, N-[(1,1-dimethyl-1H-inden-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620175-20-4 ZCAPLUS
CN 2-Propenamide, N-[(4-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-22-6 ZCAPLUS
CN 2-Propenamide, N-methyl-N-(3-quinolinylmethyl)-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-24-8 ZCAPLUS
CN 2-Propenamide, N-methyl-N-(1-naphthalenylmethyl)-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 768378-25-2 ZCAPLUS
CN 2-Propenamide, N-[(2,9-dihydro-3H-pyrrolo[1,2-a]indol-9-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 768378-26-3 ZCAPLUS
CN 2-Propenamide, 3-(6-amino-5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 768378-29-6 ZCAPLUS
CN 2-Propenamide, N-methyl-N-(5-quinolinylmethyl)-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620175-26-0 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-[1,2,3,4-tetrahydro-3-(2-methoxyethyl)-2-oxopyrido[2,3-d]pyrimidin-6-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-28-2 ZCAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1,2,3,4-tetrahydro-6-[(1E)-3-[methyl[(1-methyl-1H-indol-3-yl)methyl]amino]-3-oxo-1-propen-1-yl]-2-oxo-, methyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-39-5 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methyl-2-benzofuranyl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 768378-52-5 ZCAPLUS
CN 2-Propenamide, N-[(3,2-dihydro-5-acenaphthylenyl)methyl]-N-methyl-3-[1,2,3,4-tetrahydro-3-[2-(4-morpholinyl)ethyl]-2-oxopyrido[2,3-d]pyrimidin-6-yl]-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 768378-54-7 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methylbenzo[b]thien-2-yl)methyl]-3-[1,2,3,4-tetrahydro-3-[3-(4-morpholinyl)propyl]-2-oxopyrido[2,3-d]pyrimidin-6-yl]-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 768378-60-5 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-3(2H)-propanoic acid, 1,4-dihydro-6-[(1E)-3-[methyl[(3-methylbenzo[b]thien-2-yl)methyl]amino]-3-oxo-1-propen-1-yl]-2-oxo-, ethyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 768378-61-6 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)- (CA INDEX NAME)

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 768378-62-7 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)- (CA INDEX NAME)



RN 768378-63-8 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methylbenzo[b]thien-2-yl)methyl]-3-(2,3,4,5-tetrahydro-4-methyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)- (CA INDEX NAME)



RN 768378-64-9 ZCAPLUS
CN 2-Propenamide, N-[(1,2-dihydro-5-acenaphthylenyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-4-methyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)- (CA INDEX NAME)

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 894851-24-2 ZCAPLUS
CN 2-Propenamide, N-[(3-chloro-2-ethoxyphenyl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894851-29-7 ZCAPLUS
CN 2-Propenamide, N-[(3-chloro-2-propoxyphenyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 894851-36-6 ZCAPLUS
CN 2-Propenamide, N-[(3-methoxy-2-(2-methylpropoxy)phenyl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 768378-65-0 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methylbenzo[b]thien-2-yl)methyl]-3-[1,2,3,4-tetrahydro-3-[2-(4-morpholinyl)ethyl]-2-oxopyrido[2,3-d]pyrimidin-6-yl]- (CA INDEX NAME)



RN 768378-66-1 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)- (CA INDEX NAME)



RN 894851-14-0 ZCAPLUS
CN 2-Propenamide, N-[[2-ethoxy-3-(trifluoromethoxy)phenyl]methyl]-N-methyl-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 894851-19-5 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[[2-propoxy-3-(trifluoromethoxy)phenyl]methyl]-3-

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 894851-44-6 ZCAPLUS
CN 2-Propenamide, N-[[2-ethoxy-3-(1-methylethyl)phenyl]methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894851-49-1 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[[3-(1-methylethyl)-2-propoxyphenyl]methyl]-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 894851-53-7 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[[3-(1-methylethyl)-2-propoxyphenyl]methyl]-3-(2,3,4,5-tetrahydro-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 894851-56-0 ZCAPLUS
CN 2-Propenamide, N-[(3-methoxy-2-(2-methylpropoxy)phenyl]methyl)-N-methyl-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 894851-70-8 ZCAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1,2,7-trihydro-6-[(1E)-3-[methyl[(3-methylbenzo[b]thien-2-yl)methyl]amino]-3-oxo-1-propen-1-yl]-2-oxo-, sodium salt (1:1) (CA INDEX NAME)

Double bond geometry as shown.



● Na

RN 894851-80-0 ZCAPLUS
CN 2-Propenamide, N-[(3-ethyl-2-benzofuranyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 894851-95-7 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 894851-97-9 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methyl-2-benzofuranyl)methyl]-3-(2,3,4,5-tetrahydro-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 894852-08-5 ZCAPLUS
CN 2-Propenamide, N-[(2-ethoxy-3-(1-methylethyl)phenyl]methyl]-N-methyl-3-(2,3,4,5-tetrahydro-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 894851-84-4 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-propyl-2-benzofuranyl)methyl]-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 894851-90-2 ZCAPLUS
CN 2-Propenamide, N-[(3-ethyl-2-benzofuranyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 894851-93-5 ZCAPLUS
CN 2-Propenamide, N-[(3-methoxy-2-propoxyphenyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 894852-11-0 ZCAPLUS
CN 2-Propenamide, N-[(3-methoxy-2-(2-methylpropoxy)phenyl]methyl)-N-methyl-3-(2,3,4,5-tetrahydro-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 894852-23-4 ZCAPLUS
CN 2-Propenamide, N-[(3-cyano-1H-indol-2-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)- (CA INDEX NAME)



RN 894852-37-0 ZCAPLUS
CN 2-Propenamide, N-[(3-methoxy-2-propoxyphenyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 894852-39-2 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(2,3,4,5-tetrahydro-4-methyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-45-0 ZCAPLUS
CN 2-Propenamide, N-[(3-chloro-2-benzofuranyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 894852-46-1 ZCAPLUS
CN 2-Propenamide, N-(1H-indol-5-ylmethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 894852-47-2 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-5-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-48-3 ZCAPLUS
CN 2-Propenamide, N-[[3-(1,1-dimethylethyl)-2-propoxyphenyl]methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-51-8 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-6-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-52-9 ZCAPLUS

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN 2-Propenamide, N-[(3,4-dihydro-2H-1,5-benzodioxepin-6-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-54-1 ZCAPLUS
CN 2-Propenamide, N-[(2,3-dihydro-2,2-dimethyl-7-benzofuranyl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-55-2 ZCAPLUS
CN 2-Propenamide, N-(1H-indol-4-ylmethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-66-5 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methyl-1H-indol-2-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 894852-77-8 ZCAPLUS
CN 2-Propenamide, N-[(5-fluoro-3-methylbenzo[b]thien-2-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-78-9 ZCAPLUS
CN 2-Propenamide, N-[(5-fluoro-1-methyl-1H-indol-2-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-79-0 ZCAPLUS
CN 2-Propenamide, N-[(3-ethyl-2-benzofuranyl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-80-3 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[[3-(1-methylethyl)-2-benzofuranyl]methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 894852-81-4 ZCAPLUS
CN 2-Propenamide, N-(5-benzofuranylmethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-82-5 ZCAPLUS
CN 2-Propenamide, N-(benzo[b]thien-5-ylmethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-84-7 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-4-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 894852-85-8 ZCAPLUS
CN 2-Propenamide, N-[(1-ethyl-1H-indol-4-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-89-2 ZCAPLUS
CN 2-Propenamide, N-(1H-benzimidazol-6-ylmethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-90-5 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methyl-2-benzofuranyl)methyl]-3-(2,3,4,5-tetrahydro-2-oxo-4-phenyl-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 894852-98-3 ZCAPLUS
CN 2-Propenamide, N-[(3,7-dimethyl-1H-indol-2-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 894853-02-2 ZCAPLUS
CN 2-Propenamide, N-[(3-ethyl-1H-indol-2-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894853-19-1 ZCAPLUS
CN 2-Propenamide, N-[(1,3-dimethyl-1H-indol-2-yl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-2-oxo-4-phenyl-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894853-32-8 ZCAPLUS
CN 2-Propenamide, N-[(7-ethyl-3-methyl-1H-indol-2-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894853-40-8 ZCAPLUS
CN 2-Propenamide, N-[(3,6-dimethyl-1H-indol-5-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Double bond geometry as shown.



RN 894853-45-3 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methyl-2-benzofuranyl)methyl]-3-(5,6,7,8-tetrahydro-6,6-dimethyl-7-oxo-1,8-naphthyridin-3-yl)- (CA INDEX NAME)



RN 934993-44-9 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[[3-(1-methylethyl)-2-propoxyphenyl]methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



IT **335029-51-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(compns. comprising multiple antibiotic agents and preparation of heterocycle FabI inhibitor)
RN 335029-51-1 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



IT **768378-27-4P** **768378-53-6P** **894851-18-4P**
894851-23-1P **894851-35-5P**,
(E)-N-(3-Chloro-2-propoxybenzyl)-3-(3,3-dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-methyl-2-propenamide

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
894851-51-5P **894851-57-1P** **894851-72-0P**
894851-82-2P, (E)-N-[(3-Ethylbenzofuran-2-yl)methyl]-N-methyl-3-(2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
894851-89-9P, (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-methyl-N-[(3-propylbenzofuran-2-yl)methyl]-2-propenamide **894851-92-4P**, (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[(3-ethylbenzofuran-2-yl)methyl]-N-methyl-2-propenamide
894851-94-6P, (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-(3-metnoxy-2-propoxybenzyl)-N-methyl-2-propenamide **894851-96-8P** **894851-99-1P**, (E)-N-Methyl-N-[(3-methylbenzofuran-2-yl)methyl]-3-(2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
894852-09-6P, (E)-N-(2-Ethoxy-3-isopropylbenzyl)-3-[4-(4-methoxybenzyl)-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-N-methyl-2-propenamide **894852-12-1P**, (E)-N-(2-Isobutoxy-3-methoxybenzyl)-N-methyl-3-(2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; compns. comprising multiple antibiotic agents and prepn. of heterocycle FabI inhibitor)
RN 768378-27-4 ZCAPLUS
CN 2-Propenamide, 3-[6-[(diphenylmethylene)amino]-5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl]-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 768378-53-6 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-3(2H)-acetic acid, 1,4-dihydro-6-[(1E)-3-[methyl[(3-methylbenzo[b]thien-2-yl)methyl]amino]-3-oxo-1-propen-1-yl]-2-oxo-, ethyl ester, sodium salt (1:1) (CA INDEX NAME)

Double bond geometry as shown.



● Na

RN 894851-18-4 ZCAPLUS
CN 2-Propenamide, N-[(2-ethoxy-3-(trifluoromethoxy)phenyl]methyl]-N-methyl-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 894851-57-1 ZCAPLUS
CN 2-Propenamide, N-[(3-methoxy-2-(2-methylpropoxy)phenyl]methyl]-N-methyl-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894851-72-0 ZCAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1,2-dihydro-6-[(1E)-3-[methyl[(3-methylbenzo[b]thien-2-yl)methyl]amino]-3-oxo-1-propen-1-yl]-2-oxo-, ethyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 894851-82-2 ZCAPLUS
CN 2-Propenamide, N-[(3-ethyl-2-benzofuranyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894851-89-9 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-propyl-2-benzofuranyl)methyl]-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 894851-23-1 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[[2-propoxy-3-(trifluoromethoxy)phenyl]methyl]-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894851-35-5 ZCAPLUS
CN 2-Propenamide, N-[(3-chloro-2-propoxyphenyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894851-51-5 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[[3-(1-methylethyl)-2-propoxyphenyl]methyl]-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 894851-92-4 ZCAPLUS
CN 2-Propenamide, N-[(3-ethyl-2-benzofuranyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894851-94-6 ZCAPLUS
CN 2-Propenamide, N-[(3-methoxy-2-propoxyphenyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894851-96-8 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894851-99-1 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methyl-2-benzofuranyl)methyl]-3-(2,3,4,5-tetrahydro-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Double bond geometry as shown.



RN 894852-09-6 ZCAPLUS
CN 2-Propenamide, N-[[2-ethoxy-3-(1-methylethyl)phenyl]methyl]-N-methyl-3-[2,3,4,5-tetrahydro-4-[(4-methoxyphenyl)methyl]-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-12-1 ZCAPLUS
CN 2-Propenamide, N-[[3-methoxy-2-(2-methylpropoxy)phenyl]methyl]-N-methyl-3-(2,3,4,5-tetrahydro-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L31 ANSWER 2 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN

AN 2005:283474 ZCAPLUS
DN 142:336396
TI Preparation of tetrahydroquinoxalines as M2 acetylcholine receptor agonists for the treatment of cardiovascular diseases
IN Kuhl, Alexander; Kolkhof, Peter; Telan, Leila; Peters, Jan-Georg; Lustig, Klemens; Kast, Raimund; Muenter, Klaus; Stasch, Johannes-Peter; Tinel, Hanna
PA Bayer Healthcare Ag, Germany
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2005028451	A1	20050331	2004WO-EP0009934	20040907 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE----10343098	A1	20050414	2003DE-10043098	20030918 <--
PRAI 2003DE-10043098	A	20030918	<--	

OS MARPAT 142:336396
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Y = A-R1; A = (un)substituted alkandiyl (sic); X = CH, N; R1 = (un)substituted Ph, pyridyl (sic); R2 = (un)substituted cycloalkyl; R3 = alkyl, cycloalkyl; R4 = H, alkyl; R5 = H, alkyl] and their pharmaceutically acceptable salts were prepared For example, EDC mediated coupling of carboxylic acid II e.g., prepared from 4-chloro-3-nitrobenzoic acid chloride in 6-steps, and (S)-(-)-(4-methoxyphenyl)ethylamine afforded tetrahydroquinoxaline III in 13% yield. In human M2 acetylcholine receptor assays, 6-examples of compds. I exhibited EC50 values ranging from 1-830 nM, e.g., the ED50 value of tetrahydroquinoxaline III was 830 nM. Compds. I are claimed to be useful for the treatment of cardiovascular diseases.
IT **848572-35-0P**, 4-Cyclopropyl-N-[(1S)-1-(4-methoxyphenyl)ethyl]-3-oxo-1,2,3,4-tetrahydropyrido[2,3-b]pyrazin-7-carboxamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tetrahydroquinoxalines as M2 acetylcholine receptor agonists for the treatment of cardiovascular diseases)
RN 848572-35-0 ZCAPLUS
CN Pyrido[2,3-b]pyrazine-7-carboxamide, 4-cyclopropyl-1,2,3,4-tetrahydro-N-[(1S)-1-(4-methoxyphenyl)ethyl]-3-oxo- (CA INDEX NAME)

Absolute stereochemistry.

L31 ANSWER 2 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 3 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN

AN 2004:799437 ZCAPLUS
DN 141:314353
TI Compositions comprising multiple antibiotic agents including a FabI inhibitor, methods of using the same, and preparation of the heterocycle FabI inhibitors
IN Berman, Judd M.; Schmid, Molly B.; Mendlein, John D.; Kaplan, Nachum
PA Affinium Pharmaceuticals, Inc., Can.
SO PCT Int. Appl., 311 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2004082586	A2	20040930	2004WO-IB0001261	20040317 <--
WO--2004082586	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA-----2519429	A1	20040930	2004CA-002519429	20040317 <--
EP-----1608377	A2	20051228	2004EP-000721257	20040317 <--
EP-----1608377	B1	20081001		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
JP--2006522207	T	20061012	2006JP-000506526	20040317 <--
AT------409485	T	20081015	2004AT-000721257	20040317 <--
US-2006142265	A1	20060629	2005US-000231298	20050919 <--
PRAI 2003US-00455189P	P	20030317	<--	
2003US-00476970P	P	20030609	<--	
2003US-00488379P	P	20030718	<--	
2004WO-IB0001261	W	20040317		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 141:314353
GI



I

AB The invention is directed to antibacterial compns. comprising an NADH (or NADPH)-dependent enoyl-acyl carrier protein (ACP) reductase (FabI, previously designated EnvM) inhibitor of formula (Y1)a-A-CH(R1)-NR1CO-L-R2 (I) and at least one other antibiotic/antibacterial agent (L = alkyl, alkenyl, or cycloalkyl which may be substituted by one or more R1; A = (un)substituted bicyclic heteroaryl of 8-12 atoms or a tricyclic ring of 12-16 atoms, containing 1-4 heteroatoms selected from N, S, and O; R1 = cyclo/alkyl, alk/aryl; R2 = heterocyclyl; a = 0-4; Y1 = -(CH2)n-CO-NR4R5; R4 = water solubilizing group; R5 = H, cyclo/alkyl; n = 0-4). The antibacterial composition exhibits a synergistic antibacterial effect compared to its individual components. Thus, reacting 7-Bromo-3,3-dimethyl-1,3,4,5-tetrahydropyrido[2,3-e][1,4]diazepin-2-one (preparation given) with N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]acrylamide (preparation given), followed by acidulation gave diazepinone salt II•HCl. Selected I inhibited FabI with a Ki < 1 nM, an MIC (minimal inhibitory concentration) < 0.125 μg/mL, and an IC50 < 10 nM.
IT **620175-38-4** **620175-39-5** **620175-40-8**
620175-43-1 **620175-44-2** **1072664-02-8**
1072664-03-9 **1072664-04-0**
RL: PRPH (Prophetic)

L31 ANSWER 3 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(Compositions comprising multiple antibiotic agents including a FabI inhibitor, methods of using the same, and preparation of the heterocycle FabI inhibitors)
RN 620175-38-4 ZCAPLUS
CN 2-Propenamide, N-(3-benzofuranylmethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-39-5 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methyl-2-benzofuranyl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-40-8 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-3-benzofuranyl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-43-1 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[1-(1-methyl-1H-indol-2-yl)ethyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



IT **486397-21-1P**, (E)-N-Methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-N-[(1,2,7-trimethyl-1H-indol-3-yl)methyl]-2-propenamide
620174-10-9P, (E)-N-Methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(3-methyl-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl)-2-propenamide
620174-11-0P, (E)-N-Methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(3-methyl-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl)-2-propenamide
620174-23-4P, (E)-N-(1H-Indol-3-ylmethyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-26-7P, (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-29-0P, (E)-N-[[1-(2-Dimethylaminoethyl)-1H-indol-3-yl]methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide **620174-32-6P** **620174-40-5P**, (E)-N-Methyl-N-[(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-42-7P, (E)-N-[(1-Ethyl-5-fluoro-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-43-8P, (E)-N-[(5-Fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-44-9P, (E)-N-[(6-Fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-45-0P, (E)-N-[(7-Fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-63-2P, (E)-N-[(7-Chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-65-4P, (E)-N-[(7-Chloro-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-67-6P, (E)-2-Methyl-N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide **620174-69-8P**, (E)-3-Methyl-N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide **620174-73-4P**, (E)-N-Methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-2-propenamide
620174-75-6P, (E)-N-[3-(2-Hydroxyethyl)-1H-indol-3-yl]methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-77-8P, (E)-N-Methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-2-propenamide
620174-79-0P, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-89-2P, (E)-N-[(2-Chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-91-6P, (E)-N-(Naphthalen-2-ylmethyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-94-9P, (E)-N-(Benzofuran-2-ylmethyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-98-3P, (E)-N-[(5-Chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620174-99-4P, (E)-N-[(6-Chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-00-0P, (E)-N-[(1,7-Dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-01-1P, (E)-N-[(1,6-Dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-02-2P, (E)-N-[(1,4-Dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-03-3P, (E)-N-[(1,5-Dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-04-4P, (E)-N-[(7-Methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-05-5P, (E)-N-[(7-Hydroxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-06-6P, (E)-N-[(4-Chloro-1-methyl-1H-indol-3-yl)methyl]-N-

L31 ANSWER 3 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620175-44-2 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[1-(1-methyl-1H-indol-3-yl)ethyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 1072664-02-8 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[1-(1H-pyrrolo[3,2-b]pyridin-3-yl)ethyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 1072664-03-9 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[1-(1H-pyrrolo[3,2-c]pyridin-3-yl)ethyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 1072664-04-0 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[1-(1H-pyrrolo[2,3-c]pyridin-3-yl)ethyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 3 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-07-7P, (E)-N-[(4-Methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-08-8P, (E)-N-[(5-Methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-10-2P, (E)-N-[(6-Methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-12-4P, (E)-N-[(3,3-Dimethyl-3H-inden-1-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-20-4P, (E)-N-[(4-Fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-22-6P, (E)-N-(Quinolin-3-ylmethyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-24-8P, (E)-N-(Naphthalen-1-ylmethyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
620175-26-0P, (E)-N-Methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-[3-(2-methoxyethyl)-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide **620175-28-2P**, (E)-N-[(1-Methyl-1H-indol-3-yl)methyl]-N-methyl-3-(6-methoxycarbonyl-7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
768378-25-2P **768378-26-3P**, (E)-N-[(1-Methyl-1H-indol-3-yl)methyl]-N-methyl-3-(6-amino-7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide **768378-29-6P**, (E)-N-Methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-N-[(quinolin-5-yl)methyl]-2-propenamide monohydrochloride
768378-52-5P, (E)[(-N-Acenaphthen-5-yl)methyl]-N-methyl-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **768378-54-7P**, (E)-N-[(3-Methylbenzo[b]thiophen-2-yl)methyl]-3-[3-[3-(morpholin-4-yl)propyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide monohydrochloride **768378-60-5P**, (E)-3-[6-[2-[Methyl[(3-methylbenzo[b]thiophen-2-yl)methyl]carbamoyl]vinyl]-2-oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]propionic acid ethyl ester **768378-61-6P**, N-Methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)acrylamide
768378-62-7P, N-Methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)acrylamide
768378-63-8P, N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)acrylamide **768378-64-9P**, N-[(Acenaphthen-5-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)acrylamide **768378-65-0P**, N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]acrylamide
768378-66-1P, N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)acrylamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bactericide; compns. comprising multiple antibiotic agents and prepn. of heterocycle FabI inhibitor)
RN 486397-21-1 ZCAPLUS
CN 2-Propenamide, N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-N-[(1,2,7-trimethyl-1H-indol-3-yl)methyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-10-9 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(1,2,3,4-tetrahydro-3-methyl-2-oxopyrido[2,3-d]pyrimidin-6-yl)-, (2E)- (CA INDEX

L31 ANSWER 3 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
NAME)

Double bond geometry as shown.



RN 620174-11-0 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(1,2,3,4-tetrahydro-3-methyl-2-oxopyrido[2,3-d]pyrimidin-6-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-23-4 ZCAPLUS
CN 2-Propenamide, N-(1H-indol-3-ylmethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-26-7 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-(phenylmethyl)-1H-indol-3-yl]methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 3 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620174-42-7 ZCAPLUS
CN 2-Propenamide, N-[(1-ethyl-5-fluoro-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-43-8 ZCAPLUS
CN 2-Propenamide, N-[(5-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-44-9 ZCAPLUS
CN 2-Propenamide, N-[(6-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L31 ANSWER 3 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620174-29-0 ZCAPLUS
CN 2-Propenamide, N-[[1-[2-(dimethylamino)ethyl]-1H-indol-3-yl]methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-33-6 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methylbenzo[b]thien-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-40-5 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 3 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 620174-45-0 ZCAPLUS
CN 2-Propenamide, N-[(7-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-63-2 ZCAPLUS
CN 2-Propenamide, N-[(7-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-65-4 ZCAPLUS
CN 2-Propenamide, N-[(7-chloro-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-67-6 ZCAPLUS
CN 2-Propenamide, N,2-dimethyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 3 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620174-69-8 ZCAPLUS
CN 2-Butenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-73-4 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(6,7,8,9-tetrahydro-8-oxo-5H-pyrido[2,3-b]azepin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-75-6 ZCAPLUS
CN 2-Propenamide, N-[[1-(2-hydroxyethyl)-1H-indol-3-yl]methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 3 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620174-91-6 ZCAPLUS
CN 2-Propenamide, N-methyl-N-(2-naphthalenylmethyl)-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-94-9 ZCAPLUS
CN 2-Propenamide, N-(2-benzofuranylmethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-98-3 ZCAPLUS
CN 2-Propenamide, N-[(5-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-99-4 ZCAPLUS
CN 2-Propenamide, N-[(6-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

L31 ANSWER 3 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620174-77-8 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(6,7,8,9-tetrahydro-8-oxo-5H-pyrido[2,3-b]azepin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-79-0 ZCAPLUS
CN 2-Propenamide, N-[(1-ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-89-2 ZCAPLUS
CN 2-Propenamide, N-[(2-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 3 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Double bond geometry as shown.



RN 620175-00-0 ZCAPLUS
CN 2-Propenamide, N-[(3,7-dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-01-1 ZCAPLUS
CN 2-Propenamide, N-[(1,6-dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-02-2 ZCAPLUS
CN 2-Propenamide, N-[(1,4-dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 3 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620175-03-3 ZCAPLUS
CN 2-Propenamide, N-[(1,5-dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-04-4 ZCAPLUS
CN 2-Propenamide, N-[(7-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-05-5 ZCAPLUS
CN 2-Propenamide, N-[(7-hydroxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 3 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620175-10-2 ZCAPLUS
CN 2-Propenamide, N-[(6-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-12-4 ZCAPLUS
CN 2-Propenamide, N-[(1,1-dimethyl-1H-inden-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-20-4 ZCAPLUS
CN 2-Propenamide, N-[(4-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L31 ANSWER 3 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620175-06-6 ZCAPLUS
CN 2-Propenamide, N-[(4-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-07-7 ZCAPLUS
CN 2-Propenamide, N-[(4-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-08-8 ZCAPLUS
CN 2-Propenamide, N-[(5-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 3 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 620175-22-6 ZCAPLUS
CN 2-Propenamide, N-methyl-N-(3-quinolinylmethyl)-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-24-8 ZCAPLUS
CN 2-Propenamide, N-methyl-N-(1-naphthalenylmethyl)-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-26-0 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-[1,2,3,4-tetrahydro-3-(2-methoxyethyl)-2-oxopyrido[2,3-d]pyrimidin-6-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-28-2 ZCAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1,2,3,4-tetrahydro-6-[(1E)-3-[methyl[(1-methyl-1H-indol-3-yl)methyl]amino]-3-oxo-1-propen-1-yl]-2-oxo-, methyl ester (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 3 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 768378-25-2 ZCAPLUS
CN 2-Propenamide, N-[(2,9-dihydro-3H-pyrrolo[1,2-a]indol-9-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 768378-26-3 ZCAPLUS
CN 2-Propenamide, 3-(6-amino-5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 768378-29-6 ZCAPLUS
CN 2-Propenamide, N-methyl-N-(5-quinolinylmethyl)-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 3 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 768378-52-5 ZCAPLUS
CN 2-Propenamide, N-[(1,2-dihydro-5-acenaphthylenyl)methyl]-N-methyl-3-[1,2,3,4-tetrahydro-3-[2-(4-morpholinyl)ethyl]-2-oxopyrido[2,3-d]pyrimidin-6-yl]-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 768378-54-7 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methylbenzo[b]thien-2-yl)methyl]-3-[1,2,3,4-tetrahydro-3-[3-(4-morpholinyl)propyl]-2-oxopyrido[2,3-d]pyrimidin-6-yl]-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 768378-60-5 ZCAPLUS

L31 ANSWER 3 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Pyrido[2,3-d]pyrimidine-3(2H)-propanoic acid, 1,4-dihydro-6-[(1E)-3-[methyl[(3-methylbenzo[b]thien-2-yl)methyl]amino]-3-oxo-1-propen-1-yl]-2-oxo-, ethyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 768378-61-6 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)- (CA INDEX NAME)



RN 768378-62-7 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)- (CA INDEX NAME)



RN 768378-63-8 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methylbenzo[b]thien-2-yl)methyl]-3-(2,3,4,5-tetrahydro-4-methyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)- (CA INDEX NAME)



RN 768378-64-9 ZCAPLUS
CN 2-Propenamide, N-[(1,2-dihydro-5-acenaphthylenyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-4-methyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-

L31 ANSWER 3 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(CA INDEX NAME)



RN 768378-65-0 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methylbenzo[b]thien-2-yl)methyl]-3-[1,2,3,4-tetrahydro-3-[2-(4-morpholinyl)ethyl]-2-oxopyrido[2,3-d]pyrimidin-6-yl]- (CA INDEX NAME)



RN 768378-66-1 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)- (CA INDEX NAME)



IT **335029-51-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(compns. comprising multiple antibiotic agents and preparation of heterocycle FabI inhibitor)
RN 335029-51-1 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



IT **768378-27-4P**, (E)-N-[(1-Methyl-1H-indol-3-yl)methyl]-N-methyl-3-[6-[(benzhydrylidene)amino]-7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl]-2-propenamide **768378-53-6P**, (E)-[6-[2-[Methyl[(3-methylbenzo[b]thiophen-2-yl)methyl]carbamoyl]vinyl]-2-

L31 ANSWER 3 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]ethanoic acid ethyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; compns. comprising multiple antibiotic agents and prepn. of heterocycle FabI inhibitor)
RN 768378-27-4 ZCAPLUS
CN 2-Propenamide, 3-[6-[(diphenylmethylene)amino]-5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl]-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 768378-53-6 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-3(2H)-acetic acid, 1,4-dihydro-6-[(2E)-3-[methyl[(3-methylbenzo[b]thien-2-yl)methyl]amino]-3-oxo-1-propen-1-yl]-2-oxo-, ethyl ester, sodium salt (1:1) (CA INDEX NAME)

Double bond geometry as shown.



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 4 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:143116 ZCAPLUS
DN 140:181461
TI Preparation of 5,6-fused 3,4-dihydro-2-pyrimidinones, in particular 5,6-benzo-1,4-dihydro-2-pyrimidinones and 1,4-dihydro-2H-pyrido[3,4-d]pyrimidin-2-ones, as matrix metalloproteinase (MMP) inhibitors, in particular MMP-13 inhibitors
IN Nahra, Joe; O'Brien, Patrick Michael; Ortwine, Daniel Fred
PA Warner-Lambert Company Llc, USA
SO PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2004014869	A2	20040219	2003WO-IB0003534	20030804 <--
	WO--2004014869	A3	20040617		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU--2003250475	A1	20040225	2003AU-0002504 75	20030804 <--
	US--20040043986	A1	20040304	2003US-000634716	20030805 <--
PRAI	2002US-00403250P	P	20020813	<--	
	2003WO-IB0003534	W	20030804	<--	

OS MARPAT 140:181461
GI



I



II

AB Title compds. I (wherein R1 = independently (un)substituted hetero/cycloalkylenyl, hetero/bicycloalkylenyl, phenylalkylenyl, naphthylalkylenyl, hetero(bi)arylalkylenyl, Ph, naphthyl, hetero(bi)aryl; R2 = independently H, alkyl, phenylalkylenyl, naphthylalkylenyl, hetero(bi)arylalkylenyl, phenyl(oxy/thioxy/sulfinyl/sulfonyl)alkylenyl; B, C, D, E = independently CR5 and derivs., N; A = C:O, CH2; R4, R5 = independently H, Me, OMe, vinyl, OH, CF3, CN, C(:O)H, C(:O)Me, CH(:NOH), NH2, etc.; or R4BA = 3,4,5,6-tetrahydropyridinyl; Q = OC(:O), CH2CO and derivs., OCNH and derivs., NH2CO and derivs. , NH2SO and derivs., trans-(H)C:C(H), cis-(H)C:C(H), pyrrolidinyl-2-one, etc.; and their pharmaceutical acceptable salts) were prepared as matrix metalloproteinase (MMP) inhibitors, in particular potent MMP-13 inhibitors (no data). 1 Synthetic example, 38 claimed compds., 6 biol. methods and 18 formulation

L31 ANSWER 4 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
examples are given. For example, I was prepd., in 5 steps, by amidation of 5-iodo-2-methylaminobenzoic acid with NH3, redn. with BH3-THF, cyclization with CDI in THF, N-alkylation of the 1-methyl-1H-quinazolin-2-one intermediate, followed by Pd-cross coupling with 3-phenyl-1-propyne. I and/or their formulations are useful for treating heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis (no data).
IT **660436-94-2P**, 4-[[6-[(4-Methoxybenzylcarbamoyl)methyl]-2-oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]methyl]benzoic acid **660436-95-3P**, 1-Methyl-3-(4-methylsulfanylbenzyl)-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid N-[(pyridin-3-yl)methyl]amide **660436-96-4P**, 3-[(4-Isopropylbenzyl)methyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid N-[(pyrimidin-5-yl)methyl]amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MMP-13 innibitor; preparation of fused dihydropyrimidinones as matrix metalloproteinase inhibitors, in particular MMP-13 inhibitors)
RN 660436-94-2 ZCAPLUS
CN Benzoic acid, 4-[[1,4-dihydro-6-[2-[[(4-methoxyphenyl)methyl]amino]-2-oxoethyl]-2-oxopyrido[2,3-d]pyrimidin-3(2H)-yl]methyl]- (CA INDEX NAME)



RN 660436-95-3 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-6-carboxamide, 1,2,3,4-tetrahydro-1-methyl-3-[[4-(methylthio)phenyl]methyl]-2-oxo-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 660436-96-4 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-6-carboxamide, 1,2,3,4-tetrahydro-3-[2-[4-(1-methylethyl)phenyl]ethyl]-2-oxo-N-(5-pyrimidinylmethyl)- (CA INDEX NAME)

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 5 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:855749 ZCAPLUS
DN 139:364946
TI Preparation of N-(heteroaryl)methylacrylamides as Fab I inhibitors
IN Burgess, Walter J.; Jakas, Dalia; Huffman, William F.; Miller, William H.; Newlander, Kenneth A.; Seefeld, Mark A.; Uzinskas, Irene N.
PA Affinium Pharmaceuticals, Inc., Can.
SO PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2003088897	A2	20031030	2002WO-US0010332	20020403 <--
	WO--2003088897	A3	20050609		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA-----2444597	A1	20021006	2002CA-002444597	20020403 <--
	AU--2002367773	A1	20031103	2002AU-000367773	20020403 <--
	JP--2005519984	T	20050707	2003JP-000585650	20020403 <--
	EP-----1560584	A2	20050810	2002EP-000807262	20020403 <--
	EP-----1560584	B1	20090114		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	AT------420640	T	20090115	2002AT-000807262	20020403 <--
	ES------2320984	T3	20090601	2002ES-000807262	20020403 <--
	US--20040147580	A1	20040729	2003US-000474315	20031006 <--
	US------7049310	B2	20060523		
	US--20060116394	A1	20060601	2005US-000284660	20051122 <--
	US------7250424	B2	20070731		
	US--20090221699	A1	20090903	2007US-000767967	20070625 <--
PRAI	2001US-00282225P	P	20010406	<--	
	2002WO-US0010332	W	20020403	<--	
	2003US-000474315	A3	20031006	<--	
	2005US-000284660	A3	20051122		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 139:364946
GI



I



II

AB Title compds. I [R = (un)substituted aryl, heteroaryl; R1, R4 = H, alkyl; R2 = H, alkyl, cycloalkyl; R3 = (un)substituted pyridinyl, naphthyridinyl, azaindolyl, pyridoazepinyl, pyridodiazepinyl; R5 = H, alkyl, CH2] were prepared for use as Fab I inhibitors, useful in the treatment of bacterial infections (no data). Thus, 2-methylindole-3-carboxaldehyde was reductively aminated to give 2-methyl-3-methylaminomethylindole which was

L31 ANSWER 5 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
acylated with acryloyl chloride and treated with 2-amino-5-bromopyrimidine to give the amide II.

IT **335029-51-1P**
RL: BYP (Byproduct); SPN (Synthetic preparation); PREP (Preparation)
(preparation of N-(heteroaryl)methylacrylamides as Fab I inhibitors)

RN 335029-51-1 ZCAPLUS

CN 2-Propenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



IT **620176-26-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-(heteroaryl)methylacrylamides as Fab I inhibitors)

RN 620176-26-3 ZCAPLUS

CN 2-Propenamide, 3-[6-[(diphenylmethylene)amino]-5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl]-N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



IT **486397-21-1P** **620174-10-9P** **620174-11-0P**
620174-23-4P **620174-26-7P** **620174-29-0P**
620174-33-6P **620174-40-5P** **620174-41-6P**
620174-42-7P **620174-43-8P** **620174-44-9P**
620174-45-0P **620174-63-2P** **620174-65-4P**
620174-67-6P **620174-69-8P** **620174-73-4P**
620174-75-6P **620174-77-8P** **620174-79-0P**
620174-89-2P **620174-91-6P** **620174-93-8P**
620174-94-9P **620174-98-3P** **620174-99-4P**
620175-00-0P **620175-01-1P** **620175-02-2P**
620175-03-3P **620175-04-4P** **620175-05-5P**
620175-06-6P **620175-07-7P** **620175-08-8P**
620175-10-2P **620175-12-4P** **620175-20-4P**
620175-22-6P **620175-24-8P** **620175-26-0P**
620175-28-2P **620175-32-8P** **620175-33-9P**
620175-34-0P **620175-38-4P** **620175-39-5P**
620175-40-8P **620175-43-1P** **620175-44-2P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(heteroaryl)methylacrylamides as Fab I inhibitors)

RN 486397-21-1 ZCAPLUS

L31 ANSWER 5 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

CN 2-Propenamide, N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-N-[(1,2,7-trimethyl-1H-indol-3-yl)methyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-10-9 ZCAPLUS

CN 2-Propenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(1,2,3,4-tetrahydro-3-methyl-2-oxopyrido[2,3-d]pyrimidin-6-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-11-0 ZCAPLUS

CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(1,2,3,4-tetrahydro-3-methyl-2-oxopyrido[2,3-d]pyrimidin-6-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-23-4 ZCAPLUS

CN 2-Propenamide, N-(1H-indol-3-ylmethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 5 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620174-26-7 ZCAPLUS

CN 2-Propenamide, N-methyl-N-[(1-(phenylmethyl)-1H-indol-3-yl]methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-29-0 ZCAPLUS

CN 2-Propenamide, N-[(1-[2-(dimethylamino)ethyl]-1H-indol-3-yl]methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-33-6 ZCAPLUS

CN 2-Propenamide, N-methyl-N-[(2-methylbenzo[b]thien-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L31 ANSWER 5 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 620174-40-5 ZCAPLUS

CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-41-6 ZCAPLUS

CN 2-Propenamide, N-[(2,3-dihydro-1H-pyrrolo[1,2-a]indol-9-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-42-7 ZCAPLUS

CN 2-Propenamide, N-[(1-ethyl-5-fluoro-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-43-8 ZCAPLUS

CN 2-Propenamide, N-[(5-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 5 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620174-44-9 ZCAPLUS
CN 2-Propenamide, N-[(6-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-45-0 ZCAPLUS
CN 2-Propenamide, N-[(7-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-63-2 ZCAPLUS
CN 2-Propenamide, N-[(7-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 5 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620174-73-4 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(6,7,8,9-tetrahydro-8-oxo-5H-pyrido[2,3-b]azepin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-75-6 ZCAPLUS
CN 2-Propenamide, N-[(1-(2-hydroxyethyl)-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-77-8 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(6,7,8,9-tetrahydro-8-oxo-5H-pyrido[2,3-b]azepin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L31 ANSWER 5 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620174-65-4 ZCAPLUS
CN 2-Propenamide, N-[(7-chloro-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-67-6 ZCAPLUS
CN 2-Propenamide, N,2-dimethyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-69-8 ZCAPLUS
CN 2-Butenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 5 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 620174-79-0 ZCAPLUS
CN 2-Propenamide, N-[(1-ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-89-2 ZCAPLUS
CN 2-Propenamide, N-[(2-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-91-6 ZCAPLUS
CN 2-Propenamide, N-methyl-N-(2-naphthalenylmethyl)-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-93-8 ZCAPLUS
CN 2-Propenamide, 3-(6-amino-5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 5 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620174-94-9 ZCAPLUS
CN 2-Propenamide, N-(2-benzofuranylmethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-98-3 ZCAPLUS
CN 2-Propenamide, N-[(5-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-99-4 ZCAPLUS
CN 2-Propenamide, N-[(6-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 5 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620175-03-3 ZCAPLUS
CN 2-Propenamide, N-[(1,5-dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-04-4 ZCAPLUS
CN 2-Propenamide, N-[(7-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-05-5 ZCAPLUS
CN 2-Propenamide, N-[(7-hydroxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L31 ANSWER 5 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620175-00-0 ZCAPLUS
CN 2-Propenamide, N-[(1,7-dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-01-1 ZCAPLUS
CN 2-Propenamide, N-[(1,6-dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-02-2 ZCAPLUS
CN 2-Propenamide, N-[(1,4-dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 5 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 620175-06-6 ZCAPLUS
CN 2-Propenamide, N-[(4-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-07-7 ZCAPLUS
CN 2-Propenamide, N-[(4-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-08-8 ZCAPLUS
CN 2-Propenamide, N-[(5-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-10-2 ZCAPLUS
CN 2-Propenamide, N-[(6-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 5 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620175-12-4 ZCAPLUS
CN 2-Propenamide, N-[(1,1-dimethyl-1H-inden-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-20-4 ZCAPLUS
CN 2-Propenamide, N-[(4-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-22-6 ZCAPLUS
CN 2-Propenamide, N-methyl-N-(3-quinolinylmethyl)-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 5 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620175-24-8 ZCAPLUS
CN 2-Propenamide, N-methyl-N-(1-naphthalenylmethyl)-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-26-0 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(1,2,3,4-tetrahydro-3-(2-methoxyethyl)-2-oxopyrido[2,3-d]pyrimidin-6-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-28-2 ZCAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1,2,3,4-tetrahydro-6-[(1E)-3-[methyl[(1-methyl-1H-indol-3-yl)methyl]amino]-3-oxo-1-propen-1-yl]-2-oxo-, methyl ester (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 5 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620175-32-8 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-33-9 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-34-0 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 5 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620175-38-4 ZCAPLUS
CN 2-Propenamide, N-(3-benzofuranylmethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-39-5 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methyl-2-benzofuranyl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-40-8 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-3-benzofuranyl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-43-1 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[1-(1-methyl-1H-indol-2-yl)ethyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 5 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620175-44-2 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[1-(1-methyl-1H-indol-3-yl)ethyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 6 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
R7 = H, alkyl, aryl, aryl, heteroaryl, etc.; n = 1-8; Z1 = alkyl; A = (non)arom., 5- or 6-membered monocycle comprising from 0 to 4 heteroatoms selected from N, O, S, etc.; m = 0-7; R2 = alkyl, halo, CN, NO2, SCF3, CF3, OCF3, etc.; R3 = H, alkyl, alkenyl, alkynyl, etc.] were prepd. Over 200 synthetic examples were provided. For instance, di-Me 4-aminoisophthalate was reacted with benzylisocyanate and heated to 95-100° overnight to give Me 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylate which was sapond. (dioxaneaq, LiOH, reflux) to give the carboxylic acid. This intermediate was coupled with benzylamine to afford II. Selected examples of I had IC50 = 2.25 - 0.001 μM for MMP13 and IC50 > 100 μM for MMP1, MMP2, MMP3, MMP7, MMP9, MMP12 and MMP14; II had IC50 = 0.193 μM for MMP13. Compds. I are useful for the treatment of osteoarthritis and rheumatoid arthritis.
IT **449210-00-8P**, 1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide **449210-03-1P**, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetranydropyrido[2,3-d]pyrimidine-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide **449210-07-5P**, 4-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]methyl]benzoic acid **449210-11-1P** **449210-12-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MMP13 inhibitor; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)
RN 449210-00-8 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-6-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro-1,3-dimethyl-2,4-dioxo- (CA INDEX NAME)



RN 449210-03-1 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-6-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro-1-methyl-2,4-dioxo-3-(phenylmethyl)- (CA INDEX NAME)



RN 449210-07-5 ZCAPLUS
CN Benzoic acid, 4-[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxopyrido[2,3-d]pyrimidin-3(2H)-yl]methyl]- (CA INDEX NAME)



L31 ANSWER 6 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:637660 ZCAPLUS
DN 137:185501
TI Preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease
IN Andrianjara, Charles; Chantel-Barvian, Nicole; Gaudilliere, Bernard; Jacobelli, Henri; Ortwine, Daniel Fred; Patt, William Chester; Pham, Ly; Kostlan, Catherine Rose; Wilson, Michael William
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 264 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2002064572	A1	20020822	2002WO-EP0001979	20020211 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA-----2437122	A1	20020822	2002CA-002437122	20020211 <--
AU--2002253070	A1	20020828	2002AU-002253070	20020211 <--
EP-----1368324	A1	20031210	2002EP-000722137	20020211 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LI, LV, FI, RO, MK, CY, AL, TR				
EE---200300384	A	20031215	2003EE-000000384	20020211 <--
HU--2003003164	A2	20040128	2003HU-000003164	20020211 <--
JP--2004523546	T	20040805	2002JP-000564505	20020211 <--
CN-----1537105	A	20041013	2002CN-000805014	20020211 <--
BR--2002007268	A	20050315	2002BR-000007268	20020211 <--
US-20020193377	A1	20021219	2002US-000075954	20020213 <--
IN---2003000738	A	20060505	2003IN-000000738	20030728 <--
ZA--2003006008	A	20041104	2003ZA-000006008	20030804 <--
NO--2003003593	A	20030813	2003NO-000003593	20030813 <--
BG------108091	A	20041230	2003BG-000108091	20030813 <--
MX--2003007248	A	20050214	2003MX-000007248	20030813 <--
PRAI 2001US-00268661P	P	20010214	<--	
2002WO-EP0001979	W	20020211	<--	

OS CASREACT 137:185501; MARPAT 137:185501
GI



I



II

AB Title compds. I [R1 = H, amino, alkyl, alkenyl, alkynyl, alkylamino, aryl, heterocycle, etc.; W = O, S, =N-R'; R' = alkyl, OH, CN; X1-3 = N, C-R6; R6 = H, alkyl, amino, alkylamino, etc.; Y = O, S, NH, N-alkyl; Z = O, S, NR7;

L31 ANSWER 6 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 449210-11-1 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-6-carboxamide, 3-[(4-cyanophenyl)methyl]-1,2,3,4-tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (CA INDEX NAME)



RN 449210-12-2 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-6-carboxamide, 3-[(4-fluorophenyl)methyl]-1,2,3,4-tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (CA INDEX NAME)



IT **449210-09-7P** **449210-10-0P**, Methyl 4-[[6-[(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]methyl]benzoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)
RN 449210-09-7 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-6-carboxamide, 1,2,3,4-tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (CA INDEX NAME)



RN 449210-10-0 ZCAPLUS
CN Benzoic acid, 4-[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxopyrido[2,3-d]pyrimidin-3(2H)-yl]methyl]-, methyl ester (CA INDEX NAME)



OSC.G 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)
RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD

L31 ANSWER 6 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 7 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:637472 ZCAPLUS
DN 137:201321
TI Preparation of substituted isophthalic acid derivatives, multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors
IN Andrianjara, Charles; Ortwine, Daniel Fred; Pavlovsky, Alexander Gregory; Roark, William Howard
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2002064080	A2	20020822	2002WO-IB0000447	20020213 <--
	WO--20020640800	A3	20021212		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA-----2437643	A1	20020822	2002CA-002437643	20020213 <--
	AU--2002228302	A1	20020828	2002AU-000228302	20020213 <--
	US-20030078276	A1	20030424	2002US-000075069	20020213 <--
	EP-----1361873	A2	20031119	2002EP-000710275	20020213 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR--2002007864	A	20040309	2002BR-000007864	20020213 <--
	JP--2004529874	T	20040930	2002JP-000563877	20020213 <--
	MX--2003007250	A	20050725	2003MX-000007250	20030813 <--
	US-20050004126	A1	20050106	2004US-000835619	20040429 <--
PRAI	2001US-0026821P	P	20010214	<--	
	2002US-000075069	B3	20020213	<--	
	2002WO-IB0000447	W	20020213	<--	

GI



I II



III

AB Title compds., I [R1 and R2 together may form a substituted aromatic ring or a heterocyclic ring; or R2 and R3 together may form substituted heterocycle; or R1, R3, or R4 = alkyl, arylalkyl, etc.; X = C, S; Y = O, N with provision when Y = N it forms a 5-membered heterocycle with R3] and II [R5, R6 = arylalkylamine, heterocyclylalkoxy, etc.; R7 = H, MeO, NO2,

L31 ANSWER 7 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
etc.], are prepd. and disclosed as matrix metalloproteinase (MMP) inhibitors. Thus, III was prepd. in five steps via cyclocondensation of diethylmalonate and benzylurea with subsequent chlorination, substitution with hydrosulfide hydrate to form an in situ intermediate that was reacted with bromoacetaldehyde dimethylacetal, followed by acid catalyzed cyclization and substitution with benzylchloroformate. III was demonstrated to inhibit MMP13 with an IC50 value (in μM) of 0.0230. I and II bind allosterically to the catalytic domain of MMP-13 and comprise a hydrophobic group, first and second hydrogen bond acceptors and at least one, and preferably both, of a third hydrogen bond acceptor and a second hydrophobic group. Cartesian coordinates for centroids of the above features are defined in the specification. When the ligand binds to MMP-13, the first, second and third (when present) hydrogen bond acceptors bond resp. with Thr245, Thr247 and Met 253, the first hydrophobic group locates within the S1' channel of MMP-13 and the second hydrophobic group (when present) is relatively open to solvent. The compds. specifically inhibit the matrix metalloproteinase-13 enzyme and thus are useful for treating diseases resulting from tissue breakdown, such as heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis.
IT **449210-09-7P** **449210-10-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)
RN 449210-09-7 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-6-carboxamide, 1,2,3,4-tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (CA INDEX NAME)



RN 449210-10-0 ZCAPLUS
CN Benzoic acid, 4-[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxopyrido[2,3-d]pyrimidin-3(2H)-yl]methyl]-, methyl ester (CA INDEX NAME)



IT **449210-00-8P** **449210-03-1P** **449210-07-5P** **449210-11-1P** **449210-12-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)
RN 449210-00-8 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-6-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro-1,3-dimethyl-2,4-dioxo- (CA INDEX NAME)

L31 ANSWER 7 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 449210-03-1 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-6-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro-1-methyl-2,4-dioxo-3-(phenylmethyl)- (CA INDEX NAME)



RN 449210-07-5 ZCAPLUS
CN Benzoic acid, 4-[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxopyrido[2,3-d]pyrimidin-3(2H)-yl]methyl]- (CA INDEX NAME)



RN 449210-11-1 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-6-carboxamide, 3-[(4-cyanophenyl)methyl]-1,2,3,4-tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (CA INDEX NAME)



RN 449210-12-2 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-6-carboxamide, 3-[(4-fluorophenyl)methyl]-1,2,3,4-tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (CA INDEX NAME)



L31 ANSWER 7 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

OSC.G 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (21 CITINGS)

L31 ANSWER 8 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN

AN 2001:283945 ZCAPLUS

DN 134:311106

TI Preparation of N-heteroarylmethyl acrylamides as Fab I inhibitors

IN Miller, William H.; Newlander, Kenneth A.; Seefeld, Mark A.; Uzinskas, Irene N.; Dewolf, Walter E., Jr.; Jakas, Dalia R.

PA Smithkline Beecham Corporation, UK

SO PCT Int. Appl., 119 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2001027103	A1	20010419	2000WO-US0027844	20001006 <--
W: AE, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CZ, DZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA-----2387016	A1	20010419	2000CA-002387016	20001006 <--
EP-----1226138	A1	20020731	2000EP-000968895	20001006 <--
EP-----1226138	B1	20041229		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR--2000014470	A	20020924	2000BR-000014470	20001006 <--
HU--2002003122	A2	20030128	2002HU-000003122	20001006 <--
HU--2002003122	A3	20040128		
JP--2003511448	T	20030325	2001JP-000530321	20001006 <--
NZ------517706	A	20040130	2000NZ-000517706	20001006 <--
AU------773218	B2	20040520	2000AU-000078747	20001006 <--
AT------285821	T	20050115	2000AT-000968895	20001006 <--
CN-----1197860	C	20050420	2000CN-000813989	20001006 <--
ES-----2231275	T3	20050516	2000ES-000968895	20001006 <--
IL------148820	A	20070819	2000IL-000148820	20001006 <--
TW------534909	B	20030601	2000TW-089120828	20001128 <--
IN---200200326	A	20050318	2002IN-000000326	20020318 <--
US-----6846819	B1	20050125	2002US-000089755	20020403 <--
ZA--2002002631	A	20030320	2002ZA-000002631	20020404 <--
NO--2002001638	A	20020605	2002NO-000001638	20020405 <--
NO------322708	B1	20061127		
KR------823382	B1	20080417	2002KR-000704456	20020406 <--
US-20050250810	A1	20051110	2004US-000007927	20041209 <--
US-----7557125	B2	20090707		
US-20080125423	A1	20080529	2007US-000779578	20070718 <--
US-----7524843	B2	20090428		

PRAI 1999US-0015870 4P P 19991008 <--
2000WO-US0027844 W 20001006 <--
2002US-000089755 A1 20020403 <--
2004US-000007927 A1 20041209

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 134:311106

GI



I



II

L31 ANSWER 8 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

AB The title compds. [I; R = (un)substituted 2-indolyl, 3-quinolinyl, 1-naphthyl, etc.; R2 = H, alkyl, cycloalkyl; R3 = (un)substituted 3-pyridyl, Ph, 3-pyrimidinyl, etc.; R4 = H, alkyl; R5 = CH2 or H, alkyl (depending on double or single bond attached)] which are Fab I inhibitors and are useful in the treatment of bacterial infections, were prepared Thus, amidation (E)-3-(6-aminopyridin-3-yl)acrylic acid with 1-methyl-2-(methylaminomethyl)-1H-indole (preps. were given) in the presence of EDC, HOBt and Et3N in DMF afforded 83% (E)-II. The compds. I showed 0.05-100 μM in E. coli FabI enzyme inhibition assay.

IT **335028-13-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of N-heteroarylmethyl acrylamides as Fab I inhibitors)

RN 335028-13-2 ZCAPLUS

CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



IT **335028-19-8P** **335028-40-5P** **335029-20-4P**
335029-32-8P **335029-51-1P** **335029-58-8P**
335029-90-8P **335029-93-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-heteroarylmethyl acrylamides as Fab I inhibitors)

RN 335028-19-8 ZCAPLUS

CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(1,2,3,4-tetrahydro-3-methyl-2-oxopyrido[2,3-d]pyrimidin-6-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 335028-40-5 ZCAPLUS

CN 2-Propenamide, N-methyl-N-[(3-methyl-1H-inden-2-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 8 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 335029-20-4 ZCAPLUS

CN 2-Propenamide, N-[(1,3-dimethyl-1H-indol-2-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 335029-32-8 ZCAPLUS

CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 335029-51-1 ZCAPLUS

CN 2-Propenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 335029-58-8 ZCAPLUS

CN 1,8-Naphthyridine-3-propanamide, 5,6,7,8-tetrahydro-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-7-oxo- (CA INDEX NAME)

L31 ANSWER 8 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 335029-90-8 ZCAPLUS
CN 2-Propenamide, N-[(1,2-dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 335029-93-1 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methylbenzo[b]thien-2-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 9 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN
AN 1999:470677 ZCAPLUS
DN 131:228622
TI Replacement of the quinoline system in 2-phenyl-4-quinolinecarboxamide NK-3 receptor antagonists
AU Giardina, G. A. M.; Artico, M.; Cavagnera, S.; Cerri, A.; Consolandi, E.; Gagliardi, S.; Graziani, D.; Grugni, M.; Hay, D. W. P.; Luttmann, M. A.; Mena, R.; Raveglia, L. F.; Rigolio, R.; Sarau, H. M.; Schmidt, D. B.; Zanoni, G.; Farina, C.
CS Department of Medicinal Chemistry, SmithKline Beecham S.p.A., Milan, 20021, Italy
SO Farmaco (**1999**), 54(6), 364-374
CODEN: FPMCE8; ISSN: 0014-827X
PB Elsevier Science S.A.
DT Journal
LA English
OS CASREACT 131:228622
GI



AB Results from a medicinal chemical approach aimed at replacing the quinoline ring system in the potent and selective human neurokinin-3 (hNK-3) receptor antagonists (RS)-I (R = MeOCO, Et; X1 = C; X2 = N), (R)-I (R = MeOCO; X1 = C; X2 = N) and (S)-I (R = Et; X1 = C; X2 = N) are discussed. The data give further insight upon the potential NK-3 pharmacophore. In particular, it is highlighted that both the benzene-condensed ring and the quinoline nitrogen are crucial determinants for optimal binding affinity to the hNK-3 receptor. Some novel compds. I (R = MeOCO; X1 = X2 = C (II); R = MeOCO; X1 = X2 = N) and III (R1R2 = N:CHCH:N, CH2CH2CH2CH2) maintained part of the binding affinity to the receptor and compound II, featuring the naphthalene ring system, appears to be suitable for further modifications; it offers the option to introduce electron-withdrawing groups at position 2 and 4, conferring on the ring an overall electron-deficiency similar to that of the quinoline.
IT **244090-28-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, binding affinity and structure-activity relationsnip of NK-3 receptor antagonists)
RN 244090-28-6 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-5-carboxamide, 1,2,3,4-tetrahydro-2,4-dioxo-7-phenyl-N-(1-phenylpropyl)- (CA INDEX NAME)



OSC.G 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 9 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

L31 ANSWER 10 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN
AN 1987:458977 ZCAPLUS
DN 107:58977
ORFE 107:9796n,9797a
TI Synthesis and properties of amides of 1-benzyl-3-methyl- and 1-butyl-3-phenyl-7-methyl-4-oxo-2-thioxo (2,4-dioxo)-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acids
AU Sladowska, H.; Zawisza, I.
CS Dep. Chem. Drugs, Sch. Med., Wroclaw, Pol.
SO Farmaco, Edizione Scientifica (**1986**), 41(12), 954-63
CODEN: FRPSAX; ISSN: 0430-0920
DT Journal
LA English
GI



AB Pyridopyrimidinecarboxamides I and II (R1 = NH2, NHCH2CH:CH2, PhCH2NH, cyclohexylamino, 2-pyrimidylamino, 1-pyrrolidinyl, piperidono, morpholino; R2 = NH2, NHCH2CH:CH2, PhCH2NH, cyclohexylamino, 1-pyrrolidinyl, piperidino, morpholino; R3 = PhCH2, Bu; R4 = Me, Ph) were prepared, and they showed anticonvulsant activity.
IT **109493-25-6P** **109493-30-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and anticonvulsant activity of)
RN 109493-25-6 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-6-carboxamide, 1,2,3,4-tetrahydro-3,7-dimethyl-4-oxo-N,1-bis(phenylmethyl)-2-thioxo- (CA INDEX NAME)



RN 109493-30-3 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-6-carboxamide, 1,2,3,4-tetrahydro-3,7-dimethyl-2,4-dioxo-N,1-bis(phenylmethyl)- (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L31 ANSWER 11 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN
AN 1984:611077 ZCAPLUS
DN 101:211077
OREF 101:31983a,31986a
TI Synthesis and properties of 2,3,4,8-tetrahydro-2,4-dioxopyrido[2,3-d]pyrimidines (5-deazalumazines) and their bis-compounds
AU Nagamatsu, Tomohisa; Koga, Masakazu; Yoneda, Fumio
CS Fac. Pharm. Sci., Kumamoto Univ., Kumamoto, 862, Japan
SO Chemical & Pharmaceutical Bulletin (**1984**), 32(5), 1699-708
CODEN: CPBTAL; ISSN: 0009-2363
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB Et pyrido[2,3-d]pyrimidine-6-carboxylates I (R = Me, Et, octyl, Ph, 4-MeC6H4, 4-ClC6H4; R1 = Me, Ph and their bis-compds. II (n = 6, 8, 10, 12) were synthesized by condensation of methyluracils III with ClCR1:C(CHO)CO2Et. Hydrolysis of I and II with base resulted in a novel rearrangement of a substituent at the 7-position onto the 6-substituent to give the pyrido[2,3-d]pyrimidines IV and their bis-compds. V. The mechanism of the rearrangement was discussed.
IT **92978-17-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 92978-17-1 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-6-carboxamide, 1,2,3,4-tetrahydro-1,3-dimethyl-2,4-dioxo-7-phenyl-N-(phenylmethyl)- (CA INDEX NAME)



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

```
=> d his

     (FILE 'HOME' ENTERED AT 15:21:23 ON 21 OCT 2009)

     FILE 'REGISTRY' ENTERED AT 15:21:48 ON 21 OCT 2009
               ACT J747B/A
               ---------
L1  (    394386)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (NC5-NC5 OR NCNC3-NC5
L2  (      8932)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (NC5-NC6 OR NC5-NCNC4
L3       403278 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (L1 OR L2)
               ---------

     FILE 'STNGUIDE' ENTERED AT 15:24:58 ON 21 OCT 2009

     FILE 'REGISTRY' ENTERED AT 15:27:08 ON 21 OCT 2009
L4               STR
L5            50 L4 SAM SUB=L3
L6         12143 L4 FULL SUB=L3
               SAV TEM J747C1/A L6
L7               STR L4
L8            50 L7 SAM SUB=L6
L9          1594 L7 FULL SUB=L6
               SAV TEM J747C1N/A L9

     FILE 'ZCAPLUS' ENTERED AT 15:40:10 ON 21 OCT 2009
L10             1 US20060183908 /PN
L11               TRA L10 1- RN :      478 TERMS

     FILE 'REGISTRY' ENTERED AT 15:40:25 ON 21 OCT 2009
L12           478 SEA L11
L13           130 L12 AND L9
L14          1464 L9 NOT L13
L15               STR L7
L16            50 L15 SAM SUB=L9
L17           932 L15 FULL SUB=L9
               SAV TEM J747C1N2/A L17
L18           128 L17 AND L12
L19           804 L17 NOT L18

     FILE 'ZCAPLUS' ENTERED AT 15:45:38 ON 21 OCT 2009
L20             4 L18
L21            31 L19
L22            21 L21 AND (PRD<20031205 OR AD<=20031205 OR PD<=20031205)
L23            10 L21 NOT L22

     FILE 'REGISTRY' ENTERED AT 15:51:52 ON 21 OCT 2009
L24           136 E1-136
L25           158 E1-158
L26            75 L24 NOT L25
L27            11 L25 AND (C25H26N4O4S OR C17H16N4O4 OR C24H22N4O2S OR C28H33N5O3
L28             5 L25 AND (C25H24N4O5 OR C26H24N4O6 OR C23H20N4O3 OR C24H27N5O3)
L29            16 L27-28

     FILE 'ZCAPLUS' ENTERED AT 17:47:08 ON 21 OCT 2009
L30            11 L29
L31            11 L30 AND L22

=>
```